The Complete Nootropics Masterclass Volume 3 (1/11) — Metabolic Cognitive Enhancers

[enchanted_elixir]

THE COMPLETE NOOTROPICS MASTERCLASS
VOLUME 3: THE LIST OF COMPOUNDS
PART 1 OF 11 | METABOLIC COGNITIVE ENHANCERS​

---

Part III — Major Nootropic Classes & Nootropic Inventory​

Prelude​

Assuming a solid baseline has been established, enhancing beyond our baseline is going to be our next grand objective.

One important notice: this guide reflects my own point of view about enhancing and modulating brain function, including cognitive endurance, focus, intelligence, and emotional resilience. The commentary and rankings should not be treated as objective or infallible; they are inevitably shaped by my preferences, experiences, and objectives.

Chapter 18 — Metabolic Cognitive Enhancers​

Your brain is expensive tissue. It is only a small fraction of body mass, yet it continuously spends energy to maintain ion gradients, recycle neurotransmitters, repair membranes, move cargo, and update synapses. A neuron does not merely need “calories.” It needs the right fuel delivered through blood, converted through the correct pathways, coupled to oxygen, and turned into ATP at the exact place and moment a signal demands it.

That makes metabolism a compelling nootropic target, but it also creates the easiest place to tell seductive stories. Raising blood NAD does not prove that neuronal NAD was limiting. Raising ketones does not prove that cognition improved. Stimulating AMPK does not reproduce exercise. A compound can move a metabolic biomarker while leaving performance unchanged—or worsening it because the original bottleneck was somewhere else.

The right question throughout this chapter is therefore: What bottleneck exists, what does the intervention actually change in humans, and did the person perform better?

18.1 What Brain Metabolism Actually Does​

Metabolism is the entire system that obtains material and energy, converts them, distributes them, and removes waste. Glucose, fatty acids, amino acids, lactate, and ketones are feedstocks. Glycolysis, the TCA cycle, and oxidative phosphorylation are processing lines. Oxygen is the final electron acceptor that lets the respiratory chain keep running. ATP is the spendable output.

Picture a neuron during intense learning. Sodium and calcium rush across its membrane, vesicles release neurotransmitter, receptors change shape, and ion pumps must restore order. If ATP production cannot keep pace, the neuron does not become slightly less intelligent in an abstract way: its electrical timing degrades, transmitter recycling slows, plasticity becomes harder to support, and the entire network begins rationing work.

18.2 Astrocytes, Lactate, and the Cellular Pit Crew​

Neurons do not work alone. Astrocytes contact blood vessels and synapses, store limited glycogen, clear glutamate, regulate ions, and can supply lactate during activity. Think of them as a pit crew positioned between the fuel line and the race car: they manage the track environment so the neuron can continue firing without poisoning itself or running dry.

This matters because a compound that changes blood fuel may still fail if transport, astrocyte support, mitochondrial function, vascular delivery, sleep, or inflammation is the limiting step. The brain is a networked energy system, not a beaker into which one pours ATP ingredients.

18.3 The Metabolic Bottleneck Map​

• Fuel delivery: Is enough glucose, lactate, ketone, or other usable substrate reaching the tissue?
• Fuel transport: Can it cross gut, blood, cell membrane, and mitochondrial membrane?
• Pathway capacity: Are enzymes, cofactors, and NAD/FAD redox carriers available?
• Electron transport: Can the respiratory chain move electrons to oxygen and maintain membrane potential?
• ATP buffering: Can high-demand tissue bridge the seconds before production catches up?
• Vascular delivery: Are blood flow, oxygenation, and endothelial response adequate?
• Signaling: Are AMPK, mTOR, insulin, stress, and inflammatory signals allocating energy appropriately?
• Waste and redox control: Can the cell manage heat, reactive chemistry, lactate, damaged proteins, and metabolites?

The same compound can be helpful in deficiency, invisible at sufficiency, and harmful in overload. That is why this chapter places human evidence and baseline state above mechanism alone.

18.4 ATP Buffering​

Spoiler: 18.4.1 Creatine Monohydrate — A Larger Emergency Energy Reserve

18.4.1 Creatine Monohydrate — A Larger Emergency Energy Reserve

What it is: Creatine monohydrate is creatine crystallized with one water molecule. It is the reference form: inexpensive, stable as a dry powder, extensively studied, and not meaningfully displaced by the more exotic creatine salts sold at higher prices.

What it may feel like: Usually nothing acute. Creatine is not a stimulant and should not create a rush, forced concentration, or obvious change in mood. Its effect becomes visible when energy demand rises: the last repetitions of a difficult set may deteriorate less, recovery between repeated bursts can improve, and sleep-deprived or energetically stressed thinking may become less brittle.

The simplest description: Creatine does not give the brain or muscles unlimited energy. It enlarges the emergency energy buffer that prevents performance from collapsing during a sudden demand.

How It Works

ATP is the immediately spendable energy used by neurons, muscles, and every other active cell. Unfortunately, a cell stores very little ATP at one time. When demand suddenly rises, mitochondria cannot always manufacture fresh ATP quickly enough.

Creatine kinase solves this short-term problem. It transfers a phosphate from phosphocreatine to used ATP—technically ADP—rapidly rebuilding usable ATP. Imagine a store during an unexpected rush. Mitochondria are the workers bringing money from the bank, while phosphocreatine is the emergency cash drawer beside the register. Creatine does not make the bank infinitely rich; it keeps the register operating while more money is being delivered.

This system exists in both muscle and brain. Muscle stores rise more easily and produce the most obvious changes, while the blood–brain barrier regulates brain entry much more tightly. Consequently, swallowing creatine can raise plasma creatine within hours while meaningful tissue effects require repeated exposure.

What It Feels Like in Real Life

At rest, most people cannot feel creatine working. The first obvious change may be one or two additional repetitions during repeated high-intensity exercise or an increase in body weight from water being drawn into muscle cells. It is not expected to improve a leisurely conversation or make ordinary reading feel stimulating.

The cognitive effect is also state-dependent. A well-rested omnivore with sufficient brain creatine may notice nothing. Someone who is vegetarian, older, sleep deprived, metabolically stressed, or performing demanding work for hours has a more plausible bottleneck for creatine to relieve.

Under sleep deprivation, the relevant experience is not necessarily feeling wide awake. Thinking simply falls apart more slowly: reaction time, short-term memory, and processing can remain available later into the night. In controlled acute studies, unusually large single doses attenuated parts of the cognitive decline produced by sleep loss, with one study observing its largest cognitive effect about four hours after ingestion and effects lasting as long as nine hours. This makes creatine one of the unusual non-stimulant compounds in the guide with direct human evidence under sleep deprivation, but it does not restore normal sleep physiology or make sleep optional. Acute sleep-deprivation study, replication

Recurring user reports divide into three broad groups:

• People who notice only physical performance and intracellular water gain.
• People who describe subtly greater mental energy, clarity, or resilience when tired.
• Complete nonresponders who cannot identify any cognitive change at all.

These patterns are consistent with a quiet metabolic buffer whose value depends upon baseline stores and the task being performed. Reports of an immediate dramatic mental transformation are less consistent with ordinary tissue-loading kinetics and may involve expectation, another ingredient, or an unusual baseline deficiency. Representative discussion, contrasting reports

Dose and How It Is Taken

Ordinary maintenance: Most exercise and long-term studies use 3–5 grams daily. Do not judge creatine from the first few doses: its ordinary benefit is evaluated after tissue stores have had time to saturate. I recommend at least 20 grams split up across the day to prevent getting a stomach ache. This is because creatine goes into muscles first and only after the muscles get their share, do they let other cell types get the creatine, this includes neurons.

Practical cognitive protocol: First establish saturation—either the optional 20-gram loading phase for five to seven days or 3–5 grams daily for three to four weeks—then maintain with 3–5 grams daily while testing demanding cognition. Brain-focused studies have used widely different regimens, and recent acute sleep-deprivation experiments used approximately 0.2–0.35 g/kg as a single monitored research dose. Those unusually large acute research doses are a different protocol and should not replace ordinary saturation.

Consistency matters more than taking creatine immediately before a workout or study session. A standard daily dose works by maintaining a tissue pool, not by creating a short-lived psychoactive peak.

Solubility and Consumption

Creatine monohydrate is water-compatible but only modestly soluble—approximately 14 grams per litre near room temperature. Micronized powder disperses more easily, and warmer water improves dissolution. Any small amount remaining at the bottom can be resuspended and consumed; perfect visual dissolution is not required for absorption.

It does not require dietary fat and does not need an empty stomach. Taking it with a meal is reasonable, especially when an empty stomach causes nausea or diarrhea. Carbohydrate and insulin can increase muscular retention under some conditions, but adding a large sugar load is unnecessary for ordinary use.

Dry creatine monohydrate is stable. Once mixed into water—particularly an acidic drink—it gradually cyclizes into creatinine. There is no need to panic and drink it within seconds, but premixing acidic creatine drinks for days is a poor practice. The strongest formulation evidence still belongs to plain creatine monohydrate. Bioavailability and formulation review

Timing and Pharmacokinetics

• Subjective onset: Commonly absent. An acute feeling is not required for the compound to be absorbed.
• Plasma onset: Creatine rises in blood within the first hour after an oral dose.
• Tmax: Usually approximately one to two hours; one human study reported 1.9 ± 0.9 hours.
• Plasma duration: Blood concentrations remain elevated for roughly three to four hours after a conventional dose.
• Plasma half-life: Short and formulation-dependent. Individual studies have reported values from roughly 30 minutes to under three hours, but plasma half-life is not the clock governing the practical effect.
• Muscle accumulation: Approximately five to seven days with loading or three to four weeks with 3–5 grams daily.
• Brain accumulation: Slower and less predictable than muscle accumulation; several weeks may be required with conventional dosing, and the optimal brain-loading regimen is not established.
• Full practical effect: For repeated high-intensity muscular work, after tissue saturation. Cognitive timing depends strongly upon baseline stores and stress; no universal time to full cognitive effect exists.
• After discontinuation: Plasma creatine falls within hours, while elevated muscle stores generally require four to six weeks to return to baseline. Brain washout has not been defined as precisely.
• Near-complete elimination: Creatine is also synthesized by the body and obtained from food, so there is no creatine-free state. The relevant washout is the return of supplemented tissue stores to the person’s normal baseline.

Creatine is absorbed efficiently—oral absorption of monohydrate is close to complete—but swallowed mass, plasma exposure, muscle storage, and brain storage remain different measurements. Once inside tissues, creatine repeatedly cycles between creatine and phosphocreatine. A small fraction spontaneously converts to creatinine each day and is removed by the kidneys. Pharmacokinetic review, tissue washout

• Absorption/bioavailability: Oral creatine monohydrate is well absorbed; food is not required, although carbohydrate or mixed meals can alter tissue uptake without making fasting necessary.
• Subjective duration: Usually there is no acute sensation; once tissue stores are saturated, the practical buffer persists continuously with daily maintenance.
• Half-life: Plasma creatine clears within hours, but that value does not describe tissue saturation or the multi-week washout.
• Accumulation/steady state: Muscle stores approach saturation in about five to seven days with loading or three to four weeks without it; brain uptake is slower and less predictable.
• Metabolism/elimination: Creatine cycles with phosphocreatine and slowly converts to creatinine, which is cleared primarily by the kidneys.

Evidence and Experiences

Evidence for repeated high-intensity exercise, strength-training support, and lean-mass gain is extensive. The cognitive literature is promising but more conditional.

A 2024 meta-analysis found small improvements in memory, attention time, and processing-speed measures, but no significant overall effect on executive function. Certainty varied across outcomes, studies were heterogeneous, and the signal is generally more convincing in older adults, vegetarians, sleep-deprived subjects, or other people with a plausible energetic bottleneck than in well-rested, adequately nourished young omnivores. Cognitive meta-analysis

Creatine therefore deserves neither of the common extremes. It is not merely a bodybuilding powder with no relevance to the brain, but it is also not a universal intelligence enhancer. Its strongest cognitive case is preserving performance when the phosphocreatine system is being challenged.

Safety, Interactions, and Monitoring

The most predictable effects are:

• Intracellular water gain and a corresponding increase in body weight.
• Nausea, loose stool, cramping, or diarrhea, especially when large amounts are taken at once.
• A modest rise in measured serum creatinine, which can be misinterpreted as reduced kidney function even when filtration is unchanged.

Dividing large doses into servings of no more than approximately 5 grams reduces gastrointestinal problems. Claims that creatine routinely causes dehydration or muscle cramps are not supported by controlled evidence in healthy users. Hair loss has not been established as a clinical effect.

Clinically important drug interactions are uncommon, but pre-existing kidney disease, severe dehydration, or medication with meaningful renal toxicity warrants medical review. Creatine should also be reported before kidney testing. When the interpretation matters, a clinician may use cystatin C or another filtration measure that is less confounded by creatine turnover.

Stop and seek assessment for markedly reduced urination, persistent vomiting or diarrhea, severe unexplained swelling, an allergic reaction, or a meaningful deterioration in kidney-function measurements. Current reviews generally find preserved GFR in healthy users, while evidence in established kidney disease is much less reassuring and long-term controlled data remain finite. 2025 renal meta-analysis

Pregnancy has insufficient human supplementation evidence for casual use. Adolescents should use a higher supervision and product-quality standard rather than assuming adult sports data automatically applies to every age and medical state.

Tolerance, Dependence, Cycling, and Monitoring

Creatine does not produce classic psychoactive tolerance, addiction, withdrawal, or receptor desensitization. Endogenous production can decrease while stores are high, but available evidence does not show stores falling below the original baseline after discontinuation.

No cycling protocol is required. A four-to-six-week washout is useful only when testing whether creatine is necessary, resolving an adverse effect, or obtaining an uncontaminated personal baseline.

Useful monitoring includes body weight, gastrointestinal tolerance, training performance, hydration habits, and—when clinically appropriate—renal measurements. Cognitive claims should be tested using a repeatable task under the condition where benefit is expected: delayed recall, reaction time, error rate, or work completed after several hours. Feeling “healthier” is too nonspecific to establish a nootropic effect.

Choose an independently tested plain creatine-monohydrate powder. Identity, heavy-metal and microbial testing, batch consistency, and accurate mass matter more than a novel salt, colorful label, or proprietary absorption claim.

Bottom Line

Creatine is not an accelerator. It is a larger emergency energy reserve. Most healthy people will not feel it arrive, but during repeated muscular work, prolonged cognitive demand, aging, or sleep deprivation, the additional phosphocreatine buffer may keep performance from collapsing as quickly and regenerating performance a lot faster. Its combination of low cost, strong biological performance evidence, plausible stress-dependent cognitive value, and comparatively favorable safety makes it one of the most defensible metabolic compounds in the guide.

18.5 Electron Transport, Membrane Redox, and Mitochondrial Cofactors​

The electron transport chain is a sequence of protein complexes embedded in the inner mitochondrial membrane. Electrons move through carriers, protons are pumped across the membrane, and ATP synthase uses the gradient like water behind a dam. A redox carrier may improve one transfer step; it does not become an entire replacement power plant.

Spoiler: 18.5.1 Pyrroloquinoline Quinone (PQQ) — A Slow Mitochondrial Signal, Not Instant Fuel

18.5.1 Pyrroloquinoline Quinone (PQQ) — A Slow Mitochondrial Signal, Not Instant Fuel

What it is: PQQ is a small redox-active quinone usually sold as PQQ disodium salt. It is not itself a meaningful calorie source and does not instantly manufacture new mitochondria after one capsule.

What it may feel like: Most people feel little or nothing acutely. Responders sometimes describe clean background energy, less fatigue, or clearer thinking without the pressure and jitter of caffeine. Others report insomnia, anxiety, a strange overstimulated state, or complete nonresponse—especially when PQQ is combined with stimulants or other mitochondrial products, making attribution difficult.

The simplest description: PQQ is better imagined as a signal that may encourage cells to maintain and adapt their energy machinery over time, not as gasoline poured directly into the brain.

How It Works

PQQ participates in redox chemistry and influences signaling connected to oxidative stress, inflammation, and mitochondrial biogenesis in laboratory models. Pathways discussed include CREB, PGC-1α, and related regulators of mitochondrial growth and maintenance.

The language must stay proportional to the evidence. A pathway becoming more active in cells or animals does not prove that a healthy human grows enough useful mitochondria to feel or perform differently. “Mitochondrial biogenesis” is a mechanistic hypothesis and biomarker story, not a synonym for unlimited energy.

What It Feels Like in Real Life

When PQQ is noticeable, the recurring description is not a stimulant punch but a lighter energetic baseline: starting tasks feels less physically costly, fatigue accumulates more slowly, or the person can remain active without feeling wired. Some users report that 20 mg is invisible while 40 mg feels distinctly energizing; others find that 20 mg worsens sleep or anxiety. Those anecdotes are useful for describing possibilities but cannot establish dose-response or incidence. Mixed energy reports, adverse-experience discussion

The controlled studies do not show a reliable first-dose psychoactive effect. Reported cognitive changes were generally assessed after eight to twelve weeks, which is much more compatible with slow adaptation, practice effects, or background metabolic change than with an acute stimulant.

Dose and How It Is Taken

Typical studied dose: 20–21.5 mg once daily of PQQ disodium salt for up to twelve weeks is the most common human cognitive-study regimen. Open-label work and safety studies have explored other amounts, but more is not automatically more effective.

PQQ disodium salt is water-soluble and does not require dietary fat for dissolution. It may be taken with or without food; taking it with breakfast is the practical default because food can reduce nausea and morning use reduces the chance that a personally activating response disrupts sleep. “Water-soluble” does not mean an empty stomach is always superior.

Solubility, Absorption, and Timing

The common disodium salt is water-soluble, while solubility and exposure depend on the exact salt and formulation. Human absorption occurs, but a widely accepted absolute oral-bioavailability percentage has not been established.

Timing and Pharmacokinetics

• Subjective onset: Often absent; anecdotes range from the first day to several weeks.
• Pharmacologic onset: Detectable systemic exposure occurs after oral dosing.
• Tmax: Approximately 2–3 hours in a small human supplementation study.
• Half-life: Approximately 3–5 hours in that study.
• Accumulation/steady state: Available data do not suggest major parent-compound accumulation with daily use.
• Full practical effect: Cognitive trials generally evaluate 8–12 weeks; there is no established time to full effect in a healthy young adult.
• Near-complete elimination: Parent PQQ should largely clear from plasma within roughly one day, but downstream gene-expression or mitochondrial effects may last longer and have not been assigned a precise human washout.

PQQ circulates at low concentrations, undergoes reduction and conjugation, and is eliminated substantially through urine. Human metabolic and CNS-distribution data are much thinner than supplement marketing implies. Human PK summary, recent human-health review

• Absorption/bioavailability: Oral absorption occurs, but absolute human bioavailability and the best formulation are not established cleanly.
• Subjective duration: Usually no distinct acute window; claimed energy or sleep changes are judged across days or weeks.
• Metabolism/elimination: Human metabolic mapping is incomplete; absorbed PQQ and related material are cleared largely through renal and biliary routes.

Evidence and Experiences

Small randomized trials using about 20 mg/day for twelve weeks have reported improvements in selected cognitive outcomes in middle-aged and older healthy Japanese adults. One later study included adults aged 20–65 and reported age-stratified signals. These are interesting results, but samples are modest, several studies are industry-connected, multiple outcomes were tested, and independent replication in young students is limited. Older-adult RCT, healthy-volunteer RCT, broader-age RCT

Evidence for a noticeable acute boost, major exercise enhancement, or reversal of ordinary sleep deprivation is inadequate. People with age-related or metabolic impairment may not represent a healthy, well-rested young reader.

Safety, Interactions, and Monitoring

Short human trials generally report good tolerability, but the database is not large enough to define rare or multi-year risk. Headache, gastrointestinal upset, appetite change, activation, anxiety, and insomnia are plausible and appear in user reports.

Formal drug-interaction data are sparse. Combining it with NAD precursors, stimulants, or multiple “mitochondrial” products makes both benefits and adverse effects harder to attribute. Kidney findings at extremely high animal exposures should not be converted into a claim that ordinary human doses damage kidneys, but serious renal disease warrants caution because human data are limited.

Stop for severe insomnia, agitation, allergic symptoms, persistent vomiting, marked urinary changes, or any significant deterioration. Pregnancy, breastfeeding, childhood, and serious liver or kidney disease lack enough evidence for casual supplementation.

Tolerance, Cycling, Product Quality, and Monitoring

PQQ is not known to cause classic dependence or withdrawal. Human tolerance data are limited, and no evidence-based cycling schedule exists. A one-week washout should remove parent-drug exposure, while a longer period may be needed to judge whether a subtle sustained effect truly disappears.

Use a verified PQQ disodium-salt product with identity, dose, heavy-metal, and microbial testing. “PQQ” on a label does not prove the exact salt or the claimed milligrams.

Track sleep, anxiety, resting energy, and a repeatable cognitive outcome across several weeks. If it feels energizing but sleep worsens, the next-day deficit can erase the apparent gain. If neither subjective function nor objective output changes, a mitochondrial story alone is not a reason to continue.

Bottom Line

PQQ is a plausible slow mitochondrial signaling supplement with a few encouraging but modest human trials. The realistic expectation is either no obvious effect or a gradual reduction in background fatigue—not instant fuel, a stimulant high, or proven intelligence enhancement.

18.6 NAD Precursors and NAD Delivery​

NAD accepts and donates electrons during fuel metabolism and is consumed by repair and signaling enzymes. Blood target engagement is measurable, but the guide separates that from cellular, mitochondrial, brain, and cognitive outcomes.

Spoiler: 18.6.1 Nicotinamide Riboside (NR) — Refilling NAD Without Guaranteeing More Brainpower

18.6.1 Nicotinamide Riboside (NR) — Refilling NAD Without Guaranteeing More Brainpower

What it is: Nicotinamide riboside is a water-soluble vitamin-B3-family nucleoside, usually supplied as stabilized NR chloride. Cells convert it through NMN into NAD+, a molecule required for energy transfer, DNA repair, and signaling.

What it may feel like: Most healthy users feel nothing acute. Some older or fatigued users describe cleaner background energy, sharper thinking, better exercise tolerance, or greater motivation after days or weeks; others report insomnia, anxiety, headache, or complete nonresponse. It should not feel like a conventional stimulant.

The simplest description: NR supplies more raw material to the NAD salvage factory. It can raise blood NAD, but extra raw material only improves performance when NAD availability was actually limiting the system.

How It Works

NR enters the NAD salvage pathway through nicotinamide-riboside kinases, becoming NMN and then NAD+. NAD+ accepts electrons during metabolism and is consumed by enzymes including sirtuins, PARPs, and CD38. Raising its availability may matter with aging, inflammation, metabolic disease, or other states of accelerated NAD consumption.

The common marketing error is to equate “blood NAD increased” with “brain energy and intelligence increased.” Blood target engagement proves that the precursor entered human metabolism; it does not prove that neuronal NAD was deficient or that cognition improved.

Dose and How It Is Taken

Human trials commonly use 300–1,000 mg/day of NR chloride, with studies ranging from 100 mg/day to 2,000 mg/day. These are studied exposures, not evidence that the top dose is superior. A practical research trial normally begins with the lowest relevant studied amount rather than treating a larger NAD rise as the objective.

NR is water-soluble and does not require fat. It may be taken with or without food; breakfast is practical because food can reduce nausea and morning dosing limits personally activating effects on sleep. NR chloride mass is not identical to elemental NR mass, so labels must state what the milligrams represent.

Timing and Pharmacokinetics

• Subjective onset: Usually absent; anecdotes range from a few hours to several weeks.
• NR Tmax: Roughly three hours in a small human PK study.
• Parent NR half-life: Short and variable; approximately 2.7 hours has been reported.
• Blood-NAD response: Can rise after a single dose and remains elevated more smoothly than parent NR concentration.
• Accumulation/full effect: Blood NAD generally rises across days and can take roughly two weeks to stabilize in small newer PK work; functional outcomes are commonly judged after 4–12 weeks.
• Near-complete elimination: Parent NR clears within roughly a day, while the expanded NAD metabolome normalizes more slowly and does not have one universally established washout.

Absolute oral bioavailability of intact NR is not known cleanly because part is converted in the gut and liver to nicotinamide and other metabolites before tissues rebuild NAD. That still represents biological availability, but it is not proof that intact NR reaches every target organ. Excess nitrogenous metabolites are methylated and excreted through urine. Human NR PK study, dose-response trial

• Absorption/bioavailability: Oral NR is absorbed and extensively converted through nicotinamide and other NAD-metabolome intermediates; a simple intact-parent percentage is not the useful exposure measure.
• Full practical effect: Blood NAD can change quickly, but functional outcomes are usually judged after 4–12 weeks.
• Subjective duration: Usually no clean acute window; reported energy or sleep changes may last through the day.
• Half-life: Parent NR is short-lived and variable; approximately 2.7 hours has been reported.
• Accumulation/steady state: Parent NR does not meaningfully accumulate, while blood NAD-related pools can rise across roughly two weeks.
• Metabolism/elimination: NR enters the NAD salvage network, is converted to nicotinamide-related metabolites, and excess material is methylated and excreted in urine.

Evidence and Experiences

Repeated trials show that NR can raise the blood NAD metabolome and is generally tolerated over weeks to months. Clinical outcomes are less consistent: selected vascular, inflammatory, neurological, metabolic, or exercise signals appear in some populations, while many trials find target engagement without meaningful functional improvement.

Healthy-young-adult cognitive evidence is weak. A user report of more energy and sharper conversation after several days is vivid but was also produced by a stack containing resveratrol, quercetin, and fisetin, so NR cannot be isolated. Sleep reduction is also not automatically a benefit; losing restorative sleep can erase any daytime gain. Representative experience

Safety, Interactions, and Monitoring

Reported effects include nausea, gastrointestinal upset, headache, fatigue, flushing-like warmth, activation, and sleep disruption. Larger chronic NAD-precursor loads increase nicotinamide turnover and methylated metabolites; the clinical importance of this in healthy users remains unsettled.

Serious liver or kidney disease, pregnancy, breastfeeding, active cancer treatment, and complex metabolic medication deserve clinician review. Claims that NR necessarily accelerates cancer are not established, but NAD biology supports both healthy-cell function and tumor-cell metabolism, so active cancer is not a casual self-experiment.

Classic dependence and withdrawal are not expected, and no evidence-based cycling rule exists. Track sleep, resting heart rate, blood pressure when relevant, fatigue, exercise or cognitive output, and clinically appropriate liver, kidney, glucose, or lipid measures. Choose a verified NR-chloride product with batch identity and potency testing; degradation and under-dosing make results uninterpretable.

Bottom Line

NR reliably enters human NAD metabolism, but the felt and functional payoff depends on baseline age, illness, and metabolic demand. It is a slow metabolic precursor—not an instant focus drug—and a higher NAD number is not itself a nootropic outcome.

Spoiler: 18.6.2 Nicotinamide Mononucleotide (NMN) — One Step Closer to NAD, Still Not a Cognitive Shortcut

18.6.2 Nicotinamide Mononucleotide (NMN) — One Step Closer to NAD, Still Not a Cognitive Shortcut

What it is: Beta-nicotinamide mononucleotide is a water-soluble nucleotide directly upstream of NAD+. Oral NMN may be absorbed, dephosphorylated to NR, or converted through gut and liver pathways before its atoms appear in NAD.

What it may feel like: The modal experience is subtle or nothing. Responders describe broad, calm energy, easier exercise, or clearer focus rather than caffeine-like pressure. A minority report a pronounced surge, racing heart, dizziness, insomnia, or an initial good period followed by fatigue.

The simplest description: NMN delivers NAD-building material one biochemical step closer to the final product, but the digestive system can take that material apart and rebuild it. “Closer on a pathway diagram” does not guarantee better delivery to the brain.

How It Works

NMN is converted to NAD+ by NMN adenylyltransferases. NAD+ then supports redox energy transfer and enzymes involved in repair, stress signaling, and gene regulation. Oral human studies generally find higher blood NAD or downstream metabolites, although intact plasma NMN does not rise consistently.

This is a supply-side intervention. It may help when age or disease has lowered NAD availability; it will not correct sleep deprivation, iron deficiency, hypothyroidism, inadequate calories, or a damaged cardiovascular system simply because all of those problems eventually touch metabolism.

Dose and How It Is Taken

Common human trials use 250–300 mg once daily, while dose-ranging studies have used 300, 600, or 900 mg/day for roughly two months. A 2026 EFSA assessment considered a proposed supplement maximum of 300 mg/day for adults; jurisdictional regulatory status can change and should be checked where the reader lives.

NMN is water-soluble and does not need dietary fat. Morning oral dosing with or without breakfast is the most defensible practical route. Food can reduce stomach discomfort, and there is no good evidence that an empty stomach, liposomal formulation, or holding powder under the tongue reliably produces superior brain delivery. A 2026 crossover study found different early metabolites after sublingual administration, but this is not the same as proven superior outcomes.

Timing and Pharmacokinetics

• Subjective onset: Commonly absent; anecdotes range from hours to several weeks.
• Parent NMN Tmax/half-life: No single reliable human value is established because intact NMN is transient and studies often detect metabolites rather than parent compound.
• Metabolic onset: Downstream NAD metabolites can change within hours after an oral dose.
• Accumulation/steady state: Blood NAD changes develop over days; small precursor studies suggest roughly two weeks to a plateau.
• Full practical effect: Human functional trials usually assess 6–12 weeks.
• Near-complete elimination: Intact parent exposure is brief, but expanded blood NAD and downstream signaling normalize across days rather than on the parent-molecule clock; no universal washout is validated.

Absolute bioavailability of intact NMN is unresolved. Human studies show increases in NAMN, nicotinamide catabolites, and blood NAD even when plasma NMN itself does not rise, indicating substantial processing before or during uptake. Controlled metabolism study, older-men trial

• Absorption/bioavailability: Oral exposure is demonstrated, but intact NMN versus dephosphorylated NR and downstream metabolites cannot be summarized by one settled human percentage.
• Subjective duration: Usually no distinct acute window; occasional activation or insomnia may occupy the dosing day.
• Half-life: No dependable single human parent-NMN half-life is established because intact exposure is transient and assays often emphasize metabolites.
• Metabolism/elimination: NMN enters NAD salvage directly or after dephosphorylation, with excess nicotinamide-related metabolites ultimately cleared in urine.

Evidence and Experiences

Trials in middle-aged or older adults report reliable NAD target engagement and occasional improvements in insulin sensitivity, walking or muscle outcomes, aerobic capacity, or selected aging measures. Samples are small to moderate, follow-up is short, products and assays differ, and dramatic lifespan claims remain extrapolated from animals.

Evidence for improving cognition in healthy teenagers or young adults is inadequate. Online users describe both relaxed energy and striking activation, but also dizziness, poor sleep, racing heart, and delayed fatigue. These experiences are not incidence data and may reflect products, expectations, age, stacks, or underlying illness. Energy discussion, adverse and nonresponse discussion

Safety, Interactions, and Monitoring

Short trials generally find good tolerability. Possible complaints include gastrointestinal upset, headache, dizziness, fatigue, activation, insomnia, and palpitations. Stop for persistent tachycardia, fainting, severe dizziness, allergic reaction, jaundice, or a major change in cognition or mood.

Pregnancy, breastfeeding, childhood, serious liver or kidney disease, and active cancer treatment lack sufficient evidence for casual use. Interaction trials are sparse, so combinations with glucose-lowering medication or multiple NAD agents deserve monitoring rather than assuming biochemical compatibility.

Classic dependence is not expected, and cycling has not been shown necessary. Track sleep duration and quality, resting heart rate, blood pressure, exercise or cognitive output, and clinically relevant glucose, liver, or kidney measures. Use verified beta-NMN with identity, purity, stability, and batch-potency testing; NAD products have a documented quality-control problem.

Tolerance is not established as a classic psychoactive process, and no evidence-based cycling schedule exists.

Bottom Line

NMN can raise the human NAD metabolome, but “one step closer” does not make it a proven superior nootropic. The realistic outcome is either no felt effect or gradual background energy in a responder, with particular caution for insomnia and activation.

Spoiler: 18.6.3 5-Amino-1MQ — An NNMT Research Chemical Without Human Dosing Science

18.6.3 5-Amino-1MQ — An NNMT Research Chemical Without Human Dosing Science

What it is: 5-amino-1-methylquinolinium, usually discussed as an iodide salt, is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It is frequently marketed beside peptides, but it is not a peptide and has no established human indication.

What it may feel like: No trustworthy human signature exists. Gray-market reports describe a subtle non-stimulant leaning-out effect, steadier energy during calorie restriction, or nothing at all; others report emotional blunting, urinary symptoms, or suspected mislabeled product. Because identity was rarely verified, these are reports about purchased vials or capsules, not clean observations of 5-amino-1MQ.

The simplest description: NNMT spends nicotinamide and a methyl group. Blocking it may preserve NAD-building material and alter fat-cell metabolism—but in humans this remains an animal-derived hypothesis, not a finished drug.

How It Works

NNMT transfers a methyl group from SAM to nicotinamide, producing methyl-nicotinamide. In animal adipose research, inhibiting NNMT changes NAD and methyl-donor balance, energy expenditure, and fat accumulation. This makes the target interesting for obesity and metabolic disease.

The same mechanism creates uncertainty. Methylation and nicotinamide disposal are integrated with many pathways; blocking an enzyme is not automatically “saving NAD” without tradeoffs. Brain penetration, central selectivity, useful exposure, and long-term consequences in humans are not established.

Dose and How It Is Taken

No validated human dose exists. Online protocols commonly report approximately 25–100 mg/day orally or unvalidated injected amounts. These anecdotes cannot establish bioavailability, safety, or a starting dose and should not be presented as clinical guidance.

Public human values for oral or injected bioavailability, subjective onset, pharmacologic onset, Tmax, half-life, steady state, active metabolites, and complete elimination are missing. Claims that it works within hours or should be cycled for four weeks come from vendors and self-experimenters, not human PK trials.

Solubility depends on the exact salt; laboratory salts may be water-compatible, but solubility does not make a material sterile, injectable, or safe to swallow. Injecting research powder introduces additional contamination, endotoxin, pH, osmolarity, and sterility hazards.

Timing and Pharmacokinetics

• Subjective onset: Unknown; gray-market anecdotes range from same-day change to no effect.
• Absorption/bioavailability: Unknown in humans for oral or injected routes.
• Tmax: Unknown in humans.
• Full practical effect: Unknown; animal body-composition experiments cannot supply a human clock.
• Subjective duration: Unknown.
• Half-life: Unknown in humans.
• Accumulation/steady state: Unknown in humans.
• Near-complete elimination: Cannot be calculated without human PK.
• Metabolism/elimination: Human enzymes, metabolites, and excretion fractions are unknown.

Evidence and Experiences

The evidence base is preclinical: cell and rodent studies support NNMT as a metabolic target, but no published human Phase I dose-escalation, modern PK study, or placebo-controlled efficacy trial establishes 5-amino-1MQ as of this review.

A detailed online report described 50 mg/day orally for a month as non-stimulating, with subtle body-composition changes after two to three weeks and emotional dulling at higher exposure. Another user developed marked urination and pelvic tension after a supposed product and questioned whether it was authentic. The contradiction is the lesson: without analytical identity and controlled humans, “experience” may reflect the molecule, a contaminant, a substitute, diet, or expectation. Subtle-use report, suspected-product warning

Safety, Interactions, and Monitoring

Human adverse-effect incidence, organ toxicity, reproductive toxicity, drug interactions, tolerance, dependence, and withdrawal are unknown. The absence of reported disaster in a small online community is not a safety study.

Avoid unsupervised use in minors, pregnancy, breastfeeding, active cancer, serious liver or kidney disease, unstable psychiatric illness, or alongside complex metabolic and methylation interventions. Stop and seek care for severe urinary changes, jaundice, persistent vomiting, chest pain, fainting, neurological changes, allergic symptoms, or marked mood deterioration.

There is no evidence-based cycling or washout period. Product identity requires third-party methods capable of confirming molecular identity and quantity—not a vendor PDF that says only “purity.” Injectable use additionally requires sterility and endotoxin testing that ordinary HPLC does not provide.

Bottom Line

5-amino-1MQ is an interesting NNMT laboratory tool with essentially no human dosing or PK foundation. Its entry belongs in the guide to explain the target and the uncertainty, not to convert vendor protocols into a teenage fat-loss or nootropic regimen.

Spoiler: 18.6.4 Intravenous or Injected NAD+ — Flooding the Blood, Not Necessarily the Brain

18.6.4 Intravenous or Injected NAD+ — Flooding the Blood, Not Necessarily the Brain

What it is: NAD+ infusion places oxidized nicotinamide adenine dinucleotide directly into the bloodstream. It bypasses intestinal absorption but does not mean intact NAD+ instantly enters neurons; extracellular NAD is extensively broken into smaller metabolites before tissues reuse it.

What it may feel like: Slow infusions are often described as neutral or mildly energizing afterward. During faster infusion, chest tightness, abdominal cramping, nausea, headache, warmth, pressure in the head or ears, diarrhea, muscle tightness, weakness, and wooziness are recurring reports. These acute sensations are infusion intolerance—not proof that NAD is “flooding the mitochondria.”

The simplest description: IV NAD puts the finished molecule into blood, but cell membranes and enzymes still decide how its pieces are processed and rebuilt. Skipping the gut does not skip biology.

How It Works

Extracellular enzymes including CD38 and related nucleotidases break NAD+ into NMN, NR, nicotinamide, and other metabolites. Those components can enter salvage pathways and influence the circulating NAD metabolome. Intact NAD may also signal through purinergic and immune pathways.

In a small six-hour human infusion study, plasma NAD did not simply rise in proportion to delivery during the first two hours; metabolites rose as infused NAD was rapidly cleared and processed. This is incompatible with the clinic slogan that the drip directly fills every cell with intact NAD. Six-hour metabolism study

Dose and How It Is Taken

Published pilot work has infused approximately 750 mg over six hours or 500 mg under monitored protocols. These are research exposures, not a self-injection guide. IV administration requires a licensed clinical setting, verified sterile pharmaceutical material, line safety, and continuous response to infusion symptoms.

Timing and Pharmacokinetics

• Subjective onset: Symptoms can appear during the infusion; claimed energy benefits range from later that day to several days.
• Systemic onset: Immediate entry into blood.
• Tmax: During or at the end of infusion for delivered material, while metabolites follow different clocks.
• Half-life: A useful human terminal half-life for intact infused NAD+ has not been firmly established because extracellular metabolism is rapid and assays measure different pools.
• Full effect/accumulation: No validated schedule or time to full nootropic effect exists.
• Near-complete elimination: Unknown for the total metabolomic perturbation; clinic claims of a fixed multi-day “recharge” are not validated PK.

NAD+ is highly water-soluble. This makes aqueous infusion possible, but says nothing about sterility, stability, compatibility, or infusion rate. Intramuscular or subcutaneous “NAD injections” cannot inherit IV research because route changes the concentration, tissue exposure, pain, and contamination risk.

• Absorption/bioavailability: Intravenous delivery makes bloodstream availability immediate, but intact cellular and brain bioavailability remains limited by extracellular cleavage and membrane transport.
• Full practical effect: No validated time to maximal nootropic benefit exists; acute intolerance occurs during infusion, while claimed energy effects are judged later.
• Subjective duration: Infusion symptoms usually track the administration period; claimed after-effects range from hours to days without controlled confirmation.
• Accumulation/steady state: No validated repeated-infusion steady state exists for intact NAD or the broader metabolomic response.
• Metabolism/elimination: Extracellular enzymes rapidly cleave NAD into reusable precursors and metabolites, which enter ordinary salvage pathways and renal or biliary clearance.

Evidence and Experiences

Human evidence consists mostly of small metabolism, tolerability, and pilot studies. There is not a robust placebo-controlled program showing durable cognition, anti-aging, addiction recovery, or athletic enhancement in healthy adults.

A randomized pilot comparing oral NR, IV NR, and IV NAD found more infusion-related symptoms with NAD+ and a stronger three-hour blood-NAD rise with IV NR; the report began as a preprint and requires replication. The vivid takeaway is practical: direct NAD was not automatically the cleanest or most effective way to raise the measured blood pool. Pilot comparison

Safety, Interactions, and Monitoring

Rate-dependent nausea, abdominal or muscle cramping, diarrhea, headache, chest or head pressure, flushing, and weakness are common enough to plan for. Any IV also carries infection, phlebitis, infiltration, dosing-error, and allergic risks. Slowing the infusion may reduce ordinary symptoms, but chest pain, breathing difficulty, fainting, neurological change, severe vomiting, fever, or a line-site infection requires immediate clinical assessment.

Pregnancy, breastfeeding, minors, serious cardiovascular disease, kidney or liver disease, active cancer, and complex medication require specialist review. Unlicensed home infusion and reconstituting gray-market powder are unjustifiable.

There is no demonstrated dependence or standard cycling requirement, but repeated-clinic schedules are marketing conventions rather than outcome-validated protocols. Monitor vital signs during administration, CBC/CMP when clinically indicated, glucose, sleep, fatigue, and a predefined functional outcome. Cost must include professional administration and risk, not just milligrams.

Product and clinic quality are inseparable from risk: sterile compounding, identity, concentration, endotoxin control, line care, infusion rate, and emergency capability matter more than a wellness label.

Bottom Line

IV NAD guarantees blood delivery, not direct neuronal delivery or proven cognitive enhancement. Its human evidence remains small, infusion intolerance is common, and oral precursors are cheaper and better studied. It belongs under supervised experimental medicine, not routine supplement practice.

18.7 Ketone Precursors​

Ketones can be swallowed directly, generated from a precursor, or produced by the liver during carbohydrate restriction. These routes produce different stereochemistry, mineral load, kinetics, calories, and systemic effects. The brain can oxidize ketones, especially during sustained ketosis, but ketones do not replace oxygen or functioning mitochondria.

Spoiler: 18.7.1 R-1,3-Butanediol — Smooth Ketone Energy Without a Stimulant Push

18.7.1 R-1,3-Butanediol — Smooth Ketone Energy Without a Stimulant Push

What it is: R-1,3-butanediol is a chiral diol that the liver oxidizes through alcohol and aldehyde dehydrogenase into R-BHB. It is also the alcohol component released from several ketone esters.

What it may feel like: At modest studied beverage amounts, many people report little beyond reduced sleepiness or smooth energy. For me personally, I felt like my senses were sharper and learning was mildly improved.

The simplest description: R-1,3-butanediol is a ketone precursor: the liver converts it into R-BHB, creating a slower and smoother ketone curve than swallowing BHB directly. Alcohol dehydrogenase participates in that conversion, but sharing a metabolic enzyme with ethanol does not make the resulting experience equivalent to being drunk. You can get this stuff via a drink called Ketone-IQ.

How It Works

Alcohol dehydrogenase oxidizes R-1,3-butanediol through intermediates into R-BHB, which then circulates as fuel and signal. The R stereochemistry matters; other butanediol isomers do not share the same metabolic and safety profile.

Dose and How It Is Taken

A short human study tested three 11.5-gram servings in one day, while commercial beverages often provide roughly 10–17 grams per serving. For a first practical exposure, the conservative approach is one measured serving rather than repeated dosing, so the reader can identify whether the result is smooth ketone energy, no effect, or gastrointestinal intolerance.

R-1,3-butanediol is water-miscible and can be formulated in beverages. It does not require fat. Food may blunt and smooth the ketone curve and reduce nausea; alcohol should not be combined because the same liver enzyme system and impairment risk are involved.

Timing and Pharmacokinetics

• Subjective onset: Approximately 30–90 minutes.
• BHB onset/Tmax: BHB rises within the first hour and commonly peaks across approximately 1–3 hours.
• Subjective duration: Elevated ketones can last several hours, often longer and lower than an ester peak.
• Parent half-life/bioavailability: Modern human values are not adequately established; rapid hepatic conversion makes BHB the practical exposure marker.
• Accumulation/steady state: Repeated servings create overlapping ketone and parent exposure; safe chronic accumulation is insufficiently characterized.
• Near-complete elimination: A single serving’s ketone effect generally recedes the same day, but an exact parent washout is not validated.

Acute human tolerability study

• Absorption/bioavailability: Oral absorption and hepatic conversion are established, but a dependable absolute parent percentage is not adequately public.
• Full practical effect: The ketone effect is generally strongest across the first few hours, while impairment or nausea may define the practical limit.
• Half-life: A dependable modern human parent half-life is not established; BHB is the more useful measured exposure.
• Metabolism/elimination: Alcohol and aldehyde dehydrogenases convert R-1,3-butanediol toward R-BHB, which tissues oxidize as fuel.

Evidence and Experiences

Human evidence clearly demonstrates ketone production and short-term tolerability; cognitive-performance evidence is earlier. The practical hypothesis is straightforward: when glucose availability or metabolic endurance is the bottleneck, temporary R-BHB availability may reduce fatigue and make demanding cognition feel smoother. Anecdotes describe clean alertness, stronger sensory vividness, easier learning, reduced sleepiness, no obvious effect, or—less desirably—headache and nausea. A first exposure still should not be paired with driving or high-stakes work until the individual response is known. User-experience discussion

R-1,3-butanediol is structurally distinct from GHB and is intended to become BHB, not GHB. Similar-sounding chemistry should not be used to promise GHB-like sleep or mood effects.

Safety, Interactions, and Monitoring

Nausea, headache, gastrointestinal upset, dizziness, and taste aversion are the main practical concerns. The fact that alcohol dehydrogenase helps metabolize the compound is a biochemical fact—not proof of ethanol-like intoxication. Alcohol should still be avoided because it competes for hepatic metabolism and makes the total response harder to interpret.

Liver disease, pregnancy, breastfeeding, minors, diabetes medication, SGLT2 inhibitors, and alcohol-use disorder require avoidance or medical review. Stop for confusion, loss of coordination, persistent vomiting, severe abdominal pain, fainting, or signs of ketoacidosis.

No evidence-based cycling schedule exists, and dependence research is inadequate. Track BHB, glucose when relevant, reaction time, balance, subjective impairment, sleep, gastrointestinal effects, and the exact R-isomer dose. Product identity and stereochemical testing are essential.

Tolerance, dependence, and chronic adaptation are insufficiently characterized. Do not escalate merely to chase a “buzz”; the desired effect is stable ketone-supported energy, not intoxication.

Bottom Line

R-1,3-butanediol is a slower ketone prodrug with emerging human tolerability data and little cognitive-efficacy evidence. Its practical value is temporary alternative fuel.

18.8 Mitochondrial-Derived Peptides​

MOTS-c and humanin are short messages encoded within mitochondrial genetic regions. They are signaling hypotheses, not metabolic fuels. Endogenous associations and animal administration must be separated from safe, effective human dosing.

Spoiler: 18.8.1 MOTS-c — An Exercise Signal, Not Exercise in a Vial

18.8.1 MOTS-c — An Exercise Signal, Not Exercise in a Vial

What it is: MOTS-c is a 16-amino-acid peptide encoded within mitochondrial 12S rRNA. Human muscle and blood levels respond to exercise, while injected MOTS-c has mostly been studied in cells and animals. The clinical candidate CB4211 is a modified analog, not proof that gray-market native MOTS-c has the same PK or safety.

What it may feel like: There is no validated human signature. Self-experimenters describe improved endurance, easier recovery, steadier glucose, fatigue, headache, or no effect. When a positive effect is reported, it is most visible during a workout or prolonged demand: the person realizes late in the session that the usual collapse did not arrive as quickly. At rest, it may be imperceptible.

The simplest description: MOTS-c appears to be one of the messages mitochondria and muscle use to announce energetic stress and coordinate adaptation. Injecting the message is not equivalent to reproducing all of exercise.

How It Works

Under metabolic stress, MOTS-c can move into the nucleus and influence stress-response genes through AMPK-related pathways. Animal work suggests improved glucose uptake, insulin sensitivity, mitochondrial adaptation, and physical capacity.

In healthy men, an exercise bout increased endogenous MOTS-c in muscle approximately twelvefold and circulating levels about 1.5-fold before plasma returned toward baseline over four hours. This proves that MOTS-c participates in human exercise biology; it does not prove that an injected commercial vial improves human performance. Exercise-induced human data

Dose and How It Is Taken

There is no validated human dose for native MOTS-c. Online protocols commonly discuss milligram subcutaneous injections, but no published human PK program establishes their dose, onset, Tmax, half-life, accumulation, full effect, or washout.

CB4211 underwent early clinical testing in healthy adults and people with metabolic disease, but analog doses cannot be transferred molecule-for-molecule to native MOTS-c. The public literature does not provide enough independently reviewed detail to turn that program into a consumer schedule.

MOTS-c is a water-compatible peptide that would be destroyed or poorly absorbed when simply swallowed. This does not make research powder injectable. Sterility, endotoxin, aggregation, sequence identity, pH, and concentration are separate requirements.

Solubility and practical administration: MOTS-c is a peptide whose aqueous solubility depends on sequence, counterion, concentration, pH, and excipients. A powder dissolving in water does not prove identity, stability, sterility, or safe injection, and there is no validated consumer formulation or oral-empty-stomach rule.

Timing and Pharmacokinetics

• Anecdotal subjective onset: Same day to several weeks.
• Expected parent-peptide onset: Rapid after injection, but not quantified in humans.
• Tmax/half-life/bioavailability: Unknown for native human use.
• Full practical effect: Animal adaptation and online protocols span days to weeks; no validated human clock exists.
• Near-complete elimination: Unknown; downstream gene expression may outlast the circulating peptide.
• Subjective onset: Anecdotes range from the same day to several weeks, but there is no validated human cue.
• Absorption/bioavailability: Native oral exposure is expected to be poor; injected human absolute bioavailability and BBB delivery are unknown.
• Subjective duration: Unknown; reports describe exercise-session or day-level changes without verified exposure.
• Half-life: Unknown in humans for native MOTS-c.
• Accumulation/steady state: Unknown; downstream gene expression could outlast the parent peptide without chemical accumulation.
• Metabolism/elimination: Expected peptidase cleavage and ordinary amino-acid handling, but no human mass-balance study exists.

Evidence and Experiences

The biological evidence is strong enough to make MOTS-c scientifically important: exercise changes endogenous human MOTS-c, human genetic variation relates to metabolic phenotypes, and animal administration alters performance and glucose regulation. Actual enhancement evidence from administered native peptide in humans remains absent.

Forum reports are sparse, product identity is rarely verified, and fatigue is reported as well as endurance. That means phenomenology can be described only as a possibility, not a prediction. Mixed fatigue discussion, dose-and-evidence discussion

Safety, Interactions, and Monitoring

Human adverse-effect incidence, immunogenicity, reproductive safety, cancer implications, drug interactions, and organ toxicity are unknown for native injected MOTS-c. AMPK and glucose effects create plausible interactions with fasting, diabetes medication, metformin, and hard training. “Naturally encoded” does not mean a pharmacological injection is physiologically natural.

Avoid unsupervised use in minors, pregnancy, breastfeeding, active cancer, diabetes medication, immune disease, or serious liver and kidney disease. Stop for allergic symptoms, persistent tachycardia, severe weakness, hypoglycemic symptoms, infection, neurological change, or significant exercise intolerance.

No evidence-based cycle exists. Monitoring would require authenticated material, glucose, resting vitals, training output, recovery, sleep, injection sites, and appropriate labs. Exercise already raises endogenous MOTS-c and has vastly stronger outcome evidence.

Bottom Line

MOTS-c is a compelling exercise-responsive mitochondrial signal with inadequate administered-human evidence. It may eventually become a metabolic therapy; today, native gray-market injection remains an unvalidated experiment whose dose and PK are unknown.

Spoiler: 18.8.2 Humanin — A Cellular Distress Signal Still Looking for a Human Use

18.8.2 Humanin — A Cellular Distress Signal Still Looking for a Human Use

What it is: Humanin is a 24-amino-acid mitochondrial-derived peptide associated with cell-survival signaling. HNG, or S14G-humanin, is a much more potent synthetic analog in many laboratory assays and must not be treated as equivalent to native humanin.

What it may feel like: No repeatable controlled-human phenomenology exists. Sparse self-reports range from unusually pleasant calm, clearer cognition, or better energy to no effect; doses and identities are rarely verified. Humanin is better understood as a putative cytoprotective signal than as something expected to “hit.”

The simplest description: Humanin acts like an intracellular distress message telling vulnerable cells to resist inappropriate shutdown. Preventing unnecessary cell death may be useful in disease, but indiscriminately protecting cells can also be undesirable.

How It Works

Humanin interacts with intracellular death machinery including Bax and IGFBP-3 and with cell-surface receptor systems that activate survival pathways. Preclinical work reports neuroprotective, insulin-sensitizing, cardiovascular, and anti-inflammatory effects.

The vivid image is a building’s emergency controller refusing to demolish a damaged room while repairs are still possible. That is beneficial when a neuron is being pushed toward death by temporary stress. It may be harmful when the “room” is a malignant or irreparably damaged cell that should be removed.

Dose and How It Is Taken

There is no established human dose for native humanin or HNG. Online microgram regimens are extrapolated from animals and vendors, not Phase I trials.

• Absorption/bioavailability: Oral peptide bioavailability is expected to be poor; injected human bioavailability is unmeasured.

Timing and Pharmacokinetics

• Subjective and pharmacologic onset: Unknown in humans.
• Tmax, half-life, duration, accumulation, and elimination: Unknown for humans.
• Rodent reference: Native and analog peptides clear rapidly and distribute differently, but animal PK cannot supply a human schedule.
• Full practical effect: No validated human endpoint or clock exists.

Humanin is water-compatible as a peptide, but research solubility does not establish sterility, endotoxin control, correct folding, or suitability for injection. Rodent PK study

• Subjective onset: Unknown in humans.
• Subjective duration: Unknown because no reproducible controlled-human experience exists.
• Half-life: Unknown in humans for native humanin and its analogues.
• Accumulation/steady state: Unknown; analogues cannot inherit native-peptide assumptions.
• Near-complete elimination: Cannot be calculated without human PK.
• Metabolism/elimination: Expected peptidase cleavage, receptor-mediated uptake, and amino-acid handling; human mass balance is unavailable.

Evidence and Experiences

Human exercise studies show endogenous humanin changes in muscle or plasma, and observational work links levels with aging and metabolic states. Administered efficacy remains preclinical: cell, rodent, and mechanistic research dominate, with no well-controlled therapeutic human trials.

Reddit discussions contain far more requests for dosing than reproducible experiences. One striking “best feeling” report exists alongside many threads with no substantive follow-up, exactly the pattern in which publication and expectation bias dominate. Sparse experience thread, older subjective report

Safety, Interactions, and Monitoring

Human safety incidence, immunogenicity, reproductive toxicity, and interactions are unknown. Cytoprotection and insulin signaling create theoretical concerns in active cancer, chemotherapy, diabetes medication, and abnormal-cell survival. Experimental breast-cancer models have reported tumor-promoting effects under some conditions; this is not proof of human cancer causation, but it defeats the claim that more humanin is automatically beneficial.

Avoid unsupervised use in minors, pregnancy, breastfeeding, active or recent cancer, diabetes medication, immune disease, and serious organ disease. Stop for allergic symptoms, hypoglycemia, infection, new mass or unexplained systemic symptoms, or significant neurological deterioration.

There is no evidence-based cycling or washout. A real study would require verified sequence and analog, sterile/endotoxin-tested formulation, PK sampling, antibodies, glucose, IGF-axis measures, organ labs, and predefined functional outcomes.

Human tolerance, dependence, withdrawal, cycling, and interaction washout are unknown.

Bottom Line

Humanin is an important mitochondrial survival peptide and a poor candidate for confident self-dosing. The mechanism is promising precisely because it changes whether stressed cells live or die; that same power makes missing human safety and cancer-context data impossible to ignore.

18.9 Mitochondria-Targeted Membrane Peptides​

Elamipretide targets cardiolipin-related inner-membrane biology. It is structurally and conceptually distinct from peptides encoded by mitochondrial DNA.

Spoiler: 18.9.1 Elamipretide (SS-31; Forzinity) — Repairing the Mitochondrial Membrane, With a Real Drug Label

18.9.1 Elamipretide (SS-31; Forzinity) — Repairing the Mitochondrial Membrane, With a Real Drug Label

What it is: Elamipretide is a water-soluble four-amino-acid mitochondrial peptide that binds cardiolipin in the inner mitochondrial membrane. In 2025, the FDA granted accelerated approval as Forzinity to improve muscle strength in Barth syndrome patients weighing at least 30 kg.

What it may feel like: It is not expected to “kick in” like caffeine. Some symptomatic users describe realizing after days that they can remain active or think for longer without the usual fatigue; others report immediate energy, flat mood, tiredness, or no benefit. Injection-site redness and pain are far more dependable than a nootropic sensation.

The simplest description: Cardiolipin organizes the inner mitochondrial membrane where the respiratory chain works. Elamipretide acts less like adding fuel and more like stabilizing the workbench so the existing machinery leaks less and holds its shape.

How It Works

Elamipretide localizes to the inner mitochondrial membrane and binds cardiolipin, supporting membrane curvature, cristae structure, respiratory-chain organization, and redox efficiency. This is most compelling in Barth syndrome, where cardiolipin remodeling is genetically defective.

That disease context matters. Repairing a structurally abnormal mitochondrial membrane can improve muscle strength without implying that a healthy membrane becomes superhuman.

Dose and How It Is Taken

Approved Barth-syndrome dose: 40 mg subcutaneously once daily for patients at least 30 kg; adults with severe renal impairment who are not on dialysis receive 20 mg. This is a prescription disease dose, not a longevity or student recommendation.

Forzinity is a sterile 80 mg/mL aqueous product. The peptide is freely water-soluble, but an online lyophilized vial cannot inherit its sterility, preservative system, concentration, stability, or authorization.

Timing and Pharmacokinetics

• Subjective onset: Variable; same day to several weeks, with many nonresponders.
• Pharmacologic onset: Begins after subcutaneous absorption.
• Tmax: 0.5–1 hour.
• Absorption/bioavailability: Approximately 92%.
• Dose proportionality: Exposure is proportional across 2–80 mg daily.
• Accumulation/steady state: Minimal with once-daily dosing.
• Half-life: The public label does not present one simple terminal value suitable for consumer timing.
• Metabolism/elimination: Sequential C-terminal cleavage produces inactive M1 tripeptide and M2 dipeptide.
• Near-complete elimination: In normal renal function, approximately 100% of dose-related material was recovered in urine as parent, M1, or M2 by 48 hours.
• Full practical effect: Barth outcomes developed during weeks to months; Tmax is not the time to maximal structural or functional benefit.

FDA prescribing information

• Subjective duration: Acute sensations may occupy the injection day; disease-related functional outcomes are evaluated across weeks or months.

Evidence and Experiences

The strongest evidence belongs to a tiny, genetically defined Barth-syndrome population and an intermediate muscle-strength endpoint, with confirmatory benefit still required under accelerated approval. Trials in primary mitochondrial myopathy, heart disease, eye disease, and aging-related endpoints have produced mixed results.

Reddit reports describe both “able to go all day without fatigue” and fatigue/flat mood. They are drawn largely from ME/CFS and peptide communities using unverified products and stacks, so they illustrate possibilities rather than incidence. Mixed experience thread, ME/CFS experience report

Safety, Interactions, and Monitoring

Injection-site erythema occurred in all 12 patients in the pivotal safety population, with pain, induration, itching, bruising, and urticaria also common. Serious hypersensitivity can occur minutes to months after starting. Exposure rises substantially with renal impairment, requiring approved dose modification.

Stop and seek urgent care for breathing difficulty, facial swelling, generalized hives, fainting, or severe systemic reaction. Pregnancy data are limited; neonates must not receive the benzyl-alcohol-containing product. Gray-market injection adds infection and endotoxin risks absent from the drug label.

Classic dependence and withdrawal are not expected, but no healthy-user cycling protocol exists. Monitor renal function, injection sites, allergy, muscle strength, exercise capacity, fatigue, sleep, and the disease-specific target. Use only a prescribed authenticated product.

Classic dependence is not expected, but pharmacodynamic adaptation and tolerance have not been characterized as a healthy-use strategy; no evidence-based cycling rule exists.

Bottom Line

Elamipretide is no longer merely a research peptide: it is a narrowly approved mitochondrial drug with defined subcutaneous PK. Its real indication strengthens the cardiolipin mechanism while simultaneously showing why healthy “mitochondrial optimization” cannot borrow a rare-disease dose or promise.

18.10 Experimental Exercise Mimetics​

Exercise changes blood flow, mechanical load, temperature, calcium, hormones, neurotransmission, mitochondria, bone, muscle, and behavior. A molecule that reproduces one transcriptional program is not exercise in a capsule.

Spoiler: 18.10.1 SLU-PP-332 — Exercise-Mimetic Biology in Mice, Not a Human Shortcut

18.10.1 SLU-PP-332 — Exercise-Mimetic Biology in Mice, Not a Human Shortcut

What it is: SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors ERRα, ERRβ, and ERRγ, with the strongest activity at ERRα. Despite being sold by peptide vendors, it is not a peptide, estrogen, SARM, or approved drug.

What it may feel like: No controlled human experience exists. Online reports range from no effect to claimed endurance or fat-loss changes, but products, routes, and identities are unverified. The honest expectation is unknown—not “cardio in a vial.”

The simplest description: ERRs help write the genetic program that makes muscle more oxidative. SLU-PP-332 can switch on parts of that program in mice; it does not reproduce mechanical loading, skill practice, cardiovascular shear stress, bone loading, or every adaptation of exercise.

How It Works

ERR nuclear receptors coordinate genes involved in mitochondrial biogenesis, fatty-acid oxidation, oxidative muscle fibers, and cardiac metabolism. In mice, injected SLU-PP-332 increased endurance and energy expenditure and improved metabolic or cardiac outcomes in several disease models.

This is transcriptional pharmacology, so an effect—if humans had one—would be expected to develop through altered gene expression over days rather than as a stimulant rush.

Dose and How It Is Taken

There is no validated human dose or route. Published efficacy studies used intraperitoneal dosing in mice, commonly 25–50 mg/kg. Animal-to-human arithmetic cannot establish a safe exposure, especially when absorption and metabolism are unknown.

SLU-PP-332 is highly lipophilic and has very low aqueous solubility. It also shows poor human-liver-microsome stability, with an in-vitro half-life around 31 minutes in recent optimization work. These properties are why newer analogs are being developed; they do not validate DMSO-like injectable solvents or oral vendor capsules.

• Human oral or injected bioavailability: Unknown.
• Subjective onset, pharmacologic onset, Tmax, plasma half-life, duration, accumulation, full effect, and complete elimination: Unknown.
• Food effect: Unknown.
• BBB penetration and CNS selectivity: Not established in humans.

Chemical-optimization study

Timing and Pharmacokinetics

• Absorption/bioavailability: Unknown in humans for every proposed route.
• Full practical effect: Unknown; mouse gene-expression and endurance outcomes followed experimental exposure, not a validated human clock.
• Subjective duration: Unknown because there is no controlled human phenomenology.
• Half-life: Unknown in humans.
• Accumulation/steady state: Unknown in humans.
• Near-complete elimination: Cannot be calculated without human PK.
• Metabolism/elimination: Human metabolic enzymes, metabolites, and excretion fractions are unknown.

Evidence and Experiences

All efficacy evidence is cellular or animal. No registered, peer-reviewed human administration study establishes safety, PK, exercise performance, fat loss, or cognition. Anti-doping laboratories are already developing detection methods, which shows interest—not human safety.

Forum users themselves repeatedly note that human protocols do not exist; reports also call it a “dud.” This is precisely the setting in which mislabeled material, expectancy, and survivorship bias can manufacture a fake dose culture. Oral-bioavailability discussion, mixed anecdotal discussion

Safety, Interactions, and Monitoring

Human organ toxicity, cardiac rhythm effects, reproductive biology, cancer risk, endocrine interactions, immunological effects, and long-term ERR adaptation are unknown. ERRs are widespread metabolic regulators; “estrogen-related” does not mean hormonally inert.

Avoid human use, particularly in minors, pregnancy, breastfeeding, athletes subject to anti-doping rules, active cancer, heart disease, and combination metabolic-drug regimens. There is no evidence-based cycle or washout.

A legitimate first-in-human program would require GLP toxicology, formulation work, ECG and imaging, full metabolic and reproductive monitoring, dose escalation, PK, and long follow-up. A vendor purity chromatogram is nowhere near that standard.

Human tolerance, dependence, withdrawal, and a safe cycle are unknown. A fading sensation would not prove that ERR-driven transcriptional effects had ended.

Bottom Line

SLU-PP-332 is a valuable mouse research probe that activates part of the endurance-exercise gene program. It currently has no human dose, PK, or safety basis, and its poor solubility and metabolic stability make commercial self-experimentation even less interpretable.

---

@Volpa #Volpamogs​

 

[Fridx]

MY BEST DNR

 

[enchanted_elixir]

Volume 3 is here. Thanks to everyone who was excited to see it: @youcouldbetheone @Deathninja328 @mangotimer @psltristan1 @Leo @Jgns @ghoulmania.

The other parts will come in the next few hours as rollouts every 5-30 minutes

 

[Fridx]

I think even volpa wont read this

 

[brootaldood]

TLDR

 

[youcouldbetheone]

The Complete Nootropics Masterclass
Volume 3 — Part 1 of 11
Major Nootropic Classes, Compounds & Practical Use​

Part III — Major Nootropic Classes & Nootropic Inventory​

Prelude​

Assuming a solid baseline has been established, enhancing beyond our baseline is going to be our next grand objective.

One important notice: this guide reflects my own point of view about enhancing and modulating brain function, including cognitive endurance, focus, intelligence, and emotional resilience. The commentary and rankings should not be treated as objective or infallible; they are inevitably shaped by my preferences, experiences, and objectives.

Chapter 18 — Metabolic Cognitive Enhancers​

Your brain is expensive tissue. It is only a small fraction of body mass, yet it continuously spends energy to maintain ion gradients, recycle neurotransmitters, repair membranes, move cargo, and update synapses. A neuron does not merely need “calories.” It needs the right fuel delivered through blood, converted through the correct pathways, coupled to oxygen, and turned into ATP at the exact place and moment a signal demands it.

That makes metabolism a compelling nootropic target, but it also creates the easiest place to tell seductive stories. Raising blood NAD does not prove that neuronal NAD was limiting. Raising ketones does not prove that cognition improved. Stimulating AMPK does not reproduce exercise. A compound can move a metabolic biomarker while leaving performance unchanged—or worsening it because the original bottleneck was somewhere else.

The right question throughout this chapter is therefore: What bottleneck exists, what does the intervention actually change in humans, and did the person perform better?

18.1 What Brain Metabolism Actually Does​

Metabolism is the entire system that obtains material and energy, converts them, distributes them, and removes waste. Glucose, fatty acids, amino acids, lactate, and ketones are feedstocks. Glycolysis, the TCA cycle, and oxidative phosphorylation are processing lines. Oxygen is the final electron acceptor that lets the respiratory chain keep running. ATP is the spendable output.

Picture a neuron during intense learning. Sodium and calcium rush across its membrane, vesicles release neurotransmitter, receptors change shape, and ion pumps must restore order. If ATP production cannot keep pace, the neuron does not become slightly less intelligent in an abstract way: its electrical timing degrades, transmitter recycling slows, plasticity becomes harder to support, and the entire network begins rationing work.

18.2 Astrocytes, Lactate, and the Cellular Pit Crew​

Neurons do not work alone. Astrocytes contact blood vessels and synapses, store limited glycogen, clear glutamate, regulate ions, and can supply lactate during activity. Think of them as a pit crew positioned between the fuel line and the race car: they manage the track environment so the neuron can continue firing without poisoning itself or running dry.

This matters because a compound that changes blood fuel may still fail if transport, astrocyte support, mitochondrial function, vascular delivery, sleep, or inflammation is the limiting step. The brain is a networked energy system, not a beaker into which one pours ATP ingredients.

18.3 The Metabolic Bottleneck Map​

• Fuel delivery: Is enough glucose, lactate, ketone, or other usable substrate reaching the tissue?
• Fuel transport: Can it cross gut, blood, cell membrane, and mitochondrial membrane?
• Pathway capacity: Are enzymes, cofactors, and NAD/FAD redox carriers available?
• Electron transport: Can the respiratory chain move electrons to oxygen and maintain membrane potential?
• ATP buffering: Can high-demand tissue bridge the seconds before production catches up?
• Vascular delivery: Are blood flow, oxygenation, and endothelial response adequate?
• Signaling: Are AMPK, mTOR, insulin, stress, and inflammatory signals allocating energy appropriately?
• Waste and redox control: Can the cell manage heat, reactive chemistry, lactate, damaged proteins, and metabolites?

The same compound can be helpful in deficiency, invisible at sufficiency, and harmful in overload. That is why this chapter places human evidence and baseline state above mechanism alone.

18.4 ATP Buffering​

18.4.1 Creatine Monohydrate — A Larger Emergency Energy Reserve

What it is: Creatine monohydrate is creatine crystallized with one water molecule. It is the reference form: inexpensive, stable as a dry powder, extensively studied, and not meaningfully displaced by the more exotic creatine salts sold at higher prices.

What it may feel like: Usually nothing acute. Creatine is not a stimulant and should not create a rush, forced concentration, or obvious change in mood. Its effect becomes visible when energy demand rises: the last repetitions of a difficult set may deteriorate less, recovery between repeated bursts can improve, and sleep-deprived or energetically stressed thinking may become less brittle.

The simplest description: Creatine does not give the brain or muscles unlimited energy. It enlarges the emergency energy buffer that prevents performance from collapsing during a sudden demand.

How It Works

ATP is the immediately spendable energy used by neurons, muscles, and every other active cell. Unfortunately, a cell stores very little ATP at one time. When demand suddenly rises, mitochondria cannot always manufacture fresh ATP quickly enough.

Creatine kinase solves this short-term problem. It transfers a phosphate from phosphocreatine to used ATP—technically ADP—rapidly rebuilding usable ATP. Imagine a store during an unexpected rush. Mitochondria are the workers bringing money from the bank, while phosphocreatine is the emergency cash drawer beside the register. Creatine does not make the bank infinitely rich; it keeps the register operating while more money is being delivered.

This system exists in both muscle and brain. Muscle stores rise more easily and produce the most obvious changes, while the blood–brain barrier regulates brain entry much more tightly. Consequently, swallowing creatine can raise plasma creatine within hours while meaningful tissue effects require repeated exposure.

What It Feels Like in Real Life

At rest, most people cannot feel creatine working. The first obvious change may be one or two additional repetitions during repeated high-intensity exercise or an increase in body weight from water being drawn into muscle cells. It is not expected to improve a leisurely conversation or make ordinary reading feel stimulating.

The cognitive effect is also state-dependent. A well-rested omnivore with sufficient brain creatine may notice nothing. Someone who is vegetarian, older, sleep deprived, metabolically stressed, or performing demanding work for hours has a more plausible bottleneck for creatine to relieve.

Under sleep deprivation, the relevant experience is not necessarily feeling wide awake. Thinking simply falls apart more slowly: reaction time, short-term memory, and processing can remain available later into the night. In controlled acute studies, unusually large single doses attenuated parts of the cognitive decline produced by sleep loss, with one study observing its largest cognitive effect about four hours after ingestion and effects lasting as long as nine hours. This makes creatine one of the unusual non-stimulant compounds in the guide with direct human evidence under sleep deprivation, but it does not restore normal sleep physiology or make sleep optional. Acute sleep-deprivation study, replication

Recurring user reports divide into three broad groups:

• People who notice only physical performance and intracellular water gain.
• People who describe subtly greater mental energy, clarity, or resilience when tired.
• Complete nonresponders who cannot identify any cognitive change at all.

These patterns are consistent with a quiet metabolic buffer whose value depends upon baseline stores and the task being performed. Reports of an immediate dramatic mental transformation are less consistent with ordinary tissue-loading kinetics and may involve expectation, another ingredient, or an unusual baseline deficiency. Representative discussion, contrasting reports

Dose and How It Is Taken

Ordinary maintenance: Most exercise and long-term studies use 3–5 grams daily.

Optional muscle-loading protocol: Approximately 20 grams daily, divided into four 5-gram servings, for five to seven days, followed by 3–5 grams daily. Loading fills muscle stores faster but is not required.

Without loading: Taking 3–5 grams daily generally raises muscle stores over approximately three to four weeks.

Cognitive research: Brain-focused studies have used widely different regimens, and recent acute sleep-deprivation experiments used approximately 0.2–0.35 g/kg as a single monitored research dose. Those unusually large doses should not be converted into a casual recommendation; gastrointestinal intolerance becomes much more likely, and the evidence comes from small experimental protocols.

Consistency matters more than taking creatine immediately before a workout or study session. A standard daily dose works by maintaining a tissue pool, not by creating a short-lived psychoactive peak.

Solubility and Consumption

Creatine monohydrate is water-compatible but only modestly soluble—approximately 14 grams per litre near room temperature. Micronized powder disperses more easily, and warmer water improves dissolution. Any small amount remaining at the bottom can be resuspended and consumed; perfect visual dissolution is not required for absorption.

It does not require dietary fat and does not need an empty stomach. Taking it with a meal is reasonable, especially when an empty stomach causes nausea or diarrhea. Carbohydrate and insulin can increase muscular retention under some conditions, but adding a large sugar load is unnecessary for ordinary use.

Dry creatine monohydrate is stable. Once mixed into water—particularly an acidic drink—it gradually cyclizes into creatinine. There is no need to panic and drink it within seconds, but premixing acidic creatine drinks for days is a poor practice. The strongest formulation evidence still belongs to plain creatine monohydrate. Bioavailability and formulation review

Timing and Pharmacokinetics

• Subjective onset: Commonly absent. An acute feeling is not required for the compound to be absorbed.
• Plasma onset: Creatine rises in blood within the first hour after an oral dose.
• Tmax: Usually approximately one to two hours; one human study reported 1.9 ± 0.9 hours.
• Plasma duration: Blood concentrations remain elevated for roughly three to four hours after a conventional dose.
• Plasma half-life: Short and formulation-dependent. Individual studies have reported values from roughly 30 minutes to under three hours, but plasma half-life is not the clock governing the practical effect.
• Muscle accumulation: Approximately five to seven days with loading or three to four weeks with 3–5 grams daily.
• Brain accumulation: Slower and less predictable than muscle accumulation; several weeks may be required with conventional dosing, and the optimal brain-loading regimen is not established.
• Full practical effect: For repeated high-intensity muscular work, after tissue saturation. Cognitive timing depends strongly upon baseline stores and stress; no universal time to full cognitive effect exists.
• After discontinuation: Plasma creatine falls within hours, while elevated muscle stores generally require four to six weeks to return to baseline. Brain washout has not been defined as precisely.
• Near-complete elimination: Creatine is also synthesized by the body and obtained from food, so there is no creatine-free state. The relevant washout is the return of supplemented tissue stores to the person’s normal baseline.

Creatine is absorbed efficiently—oral absorption of monohydrate is close to complete—but swallowed mass, plasma exposure, muscle storage, and brain storage remain different measurements. Once inside tissues, creatine repeatedly cycles between creatine and phosphocreatine. A small fraction spontaneously converts to creatinine each day and is removed by the kidneys. Pharmacokinetic review, tissue washout

• Absorption/bioavailability: Oral creatine monohydrate is well absorbed; food is not required, although carbohydrate or mixed meals can alter tissue uptake without making fasting necessary.
• Subjective duration: Usually there is no acute sensation; once tissue stores are saturated, the practical buffer persists continuously with daily maintenance.
• Half-life: Plasma creatine clears within hours, but that value does not describe tissue saturation or the multi-week washout.
• Accumulation/steady state: Muscle stores approach saturation in about five to seven days with loading or three to four weeks without it; brain uptake is slower and less predictable.
• Metabolism/elimination: Creatine cycles with phosphocreatine and slowly converts to creatinine, which is cleared primarily by the kidneys.

Evidence and Experiences

Evidence for repeated high-intensity exercise, strength-training support, and lean-mass gain is extensive. The cognitive literature is promising but more conditional.

A 2024 meta-analysis found small improvements in memory, attention time, and processing-speed measures, but no significant overall effect on executive function. Certainty varied across outcomes, studies were heterogeneous, and the signal is generally more convincing in older adults, vegetarians, sleep-deprived subjects, or other people with a plausible energetic bottleneck than in well-rested, adequately nourished young omnivores. Cognitive meta-analysis

Creatine therefore deserves neither of the common extremes. It is not merely a bodybuilding powder with no relevance to the brain, but it is also not a universal intelligence enhancer. Its strongest cognitive case is preserving performance when the phosphocreatine system is being challenged.

Safety, Interactions, and Monitoring

The most predictable effects are:

• Intracellular water gain and a corresponding increase in body weight.
• Nausea, loose stool, cramping, or diarrhea, especially when large amounts are taken at once.
• A modest rise in measured serum creatinine, which can be misinterpreted as reduced kidney function even when filtration is unchanged.

Dividing large doses into servings of no more than approximately 5 grams reduces gastrointestinal problems. Claims that creatine routinely causes dehydration or muscle cramps are not supported by controlled evidence in healthy users. Hair loss has not been established as a clinical effect.

Clinically important drug interactions are uncommon, but pre-existing kidney disease, severe dehydration, or medication with meaningful renal toxicity warrants medical review. Creatine should also be reported before kidney testing. When the interpretation matters, a clinician may use cystatin C or another filtration measure that is less confounded by creatine turnover.

Stop and seek assessment for markedly reduced urination, persistent vomiting or diarrhea, severe unexplained swelling, an allergic reaction, or a meaningful deterioration in kidney-function measurements. Current reviews generally find preserved GFR in healthy users, while evidence in established kidney disease is much less reassuring and long-term controlled data remain finite. 2025 renal meta-analysis

Pregnancy has insufficient human supplementation evidence for casual use. Adolescents should use a higher supervision and product-quality standard rather than assuming adult sports data automatically applies to every age and medical state.

Tolerance, Dependence, Cycling, and Monitoring

Creatine does not produce classic psychoactive tolerance, addiction, withdrawal, or receptor desensitization. Endogenous production can decrease while stores are high, but available evidence does not show stores falling below the original baseline after discontinuation.

No cycling protocol is required. A four-to-six-week washout is useful only when testing whether creatine is necessary, resolving an adverse effect, or obtaining an uncontaminated personal baseline.

Useful monitoring includes body weight, gastrointestinal tolerance, training performance, hydration habits, and—when clinically appropriate—renal measurements. Cognitive claims should be tested using a repeatable task under the condition where benefit is expected: delayed recall, reaction time, error rate, or work completed after several hours. Feeling “healthier” is too nonspecific to establish a nootropic effect.

Choose an independently tested plain creatine-monohydrate powder. Identity, heavy-metal and microbial testing, batch consistency, and accurate mass matter more than a novel salt, colorful label, or proprietary absorption claim.

Bottom Line

Creatine is not an accelerator. It is a larger emergency energy reserve. Most healthy people will not feel it arrive, but during repeated muscular work, prolonged cognitive demand, vegetarianism, aging, or sleep deprivation, the additional phosphocreatine buffer may keep performance from collapsing as quickly. Its combination of low cost, strong physical-performance evidence, plausible stress-dependent cognitive value, and comparatively favorable safety makes it one of the most defensible metabolic compounds in the guide.

18.5 Electron Transport, Membrane Redox, and Mitochondrial Cofactors​

The electron transport chain is a sequence of protein complexes embedded in the inner mitochondrial membrane. Electrons move through carriers, protons are pumped across the membrane, and ATP synthase uses the gradient like water behind a dam. A redox carrier may improve one transfer step; it does not become an entire replacement power plant.

18.5.1 Pyrroloquinoline Quinone (PQQ) — A Slow Mitochondrial Signal, Not Instant Fuel

What it is: PQQ is a small redox-active quinone usually sold as PQQ disodium salt. It is not itself a meaningful calorie source and does not instantly manufacture new mitochondria after one capsule.

What it may feel like: Most people feel little or nothing acutely. Responders sometimes describe clean background energy, less fatigue, or clearer thinking without the pressure and jitter of caffeine. Others report insomnia, anxiety, a strange overstimulated state, or complete nonresponse—especially when PQQ is combined with stimulants or other mitochondrial products, making attribution difficult.

The simplest description: PQQ is better imagined as a signal that may encourage cells to maintain and adapt their energy machinery over time, not as gasoline poured directly into the brain.

How It Works

PQQ participates in redox chemistry and influences signaling connected to oxidative stress, inflammation, and mitochondrial biogenesis in laboratory models. Pathways discussed include CREB, PGC-1α, and related regulators of mitochondrial growth and maintenance.

The language must stay proportional to the evidence. A pathway becoming more active in cells or animals does not prove that a healthy human grows enough useful mitochondria to feel or perform differently. “Mitochondrial biogenesis” is a mechanistic hypothesis and biomarker story, not a synonym for unlimited energy.

What It Feels Like in Real Life

When PQQ is noticeable, the recurring description is not a stimulant punch but a lighter energetic baseline: starting tasks feels less physically costly, fatigue accumulates more slowly, or the person can remain active without feeling wired. Some users report that 20 mg is invisible while 40 mg feels distinctly energizing; others find that 20 mg worsens sleep or anxiety. Those anecdotes are useful for describing possibilities but cannot establish dose-response or incidence. Mixed energy reports, adverse-experience discussion

The controlled studies do not show a reliable first-dose psychoactive effect. Reported cognitive changes were generally assessed after eight to twelve weeks, which is much more compatible with slow adaptation, practice effects, or background metabolic change than with an acute stimulant.

Dose and How It Is Taken

Typical studied dose: 20–21.5 mg once daily of PQQ disodium salt for up to twelve weeks is the most common human cognitive-study regimen. Open-label work and safety studies have explored other amounts, but more is not automatically more effective.

PQQ disodium salt is water-soluble and does not require dietary fat for dissolution. It may be taken with or without food; taking it with breakfast is the practical default because food can reduce nausea and morning use reduces the chance that a personally activating response disrupts sleep. “Water-soluble” does not mean an empty stomach is always superior.

Solubility, Absorption, and Timing

The common disodium salt is water-soluble, while solubility and exposure depend on the exact salt and formulation. Human absorption occurs, but a widely accepted absolute oral-bioavailability percentage has not been established.

Timing and Pharmacokinetics

• Subjective onset: Often absent; anecdotes range from the first day to several weeks.
• Pharmacologic onset: Detectable systemic exposure occurs after oral dosing.
• Tmax: Approximately 2–3 hours in a small human supplementation study.
• Half-life: Approximately 3–5 hours in that study.
• Accumulation/steady state: Available data do not suggest major parent-compound accumulation with daily use.
• Full practical effect: Cognitive trials generally evaluate 8–12 weeks; there is no established time to full effect in a healthy young adult.
• Near-complete elimination: Parent PQQ should largely clear from plasma within roughly one day, but downstream gene-expression or mitochondrial effects may last longer and have not been assigned a precise human washout.

PQQ circulates at low concentrations, undergoes reduction and conjugation, and is eliminated substantially through urine. Human metabolic and CNS-distribution data are much thinner than supplement marketing implies. Human PK summary, recent human-health review

• Absorption/bioavailability: Oral absorption occurs, but absolute human bioavailability and the best formulation are not established cleanly.
• Subjective duration: Usually no distinct acute window; claimed energy or sleep changes are judged across days or weeks.
• Metabolism/elimination: Human metabolic mapping is incomplete; absorbed PQQ and related material are cleared largely through renal and biliary routes.

Evidence and Experiences

Small randomized trials using about 20 mg/day for twelve weeks have reported improvements in selected cognitive outcomes in middle-aged and older healthy Japanese adults. One later study included adults aged 20–65 and reported age-stratified signals. These are interesting results, but samples are modest, several studies are industry-connected, multiple outcomes were tested, and independent replication in young students is limited. Older-adult RCT, healthy-volunteer RCT, broader-age RCT

Evidence for a noticeable acute boost, major exercise enhancement, or reversal of ordinary sleep deprivation is inadequate. People with age-related or metabolic impairment may not represent a healthy, well-rested young reader.

Safety, Interactions, and Monitoring

Short human trials generally report good tolerability, but the database is not large enough to define rare or multi-year risk. Headache, gastrointestinal upset, appetite change, activation, anxiety, and insomnia are plausible and appear in user reports.

Formal drug-interaction data are sparse. Combining it with NAD precursors, stimulants, or multiple “mitochondrial” products makes both benefits and adverse effects harder to attribute. Kidney findings at extremely high animal exposures should not be converted into a claim that ordinary human doses damage kidneys, but serious renal disease warrants caution because human data are limited.

Stop for severe insomnia, agitation, allergic symptoms, persistent vomiting, marked urinary changes, or any significant deterioration. Pregnancy, breastfeeding, childhood, and serious liver or kidney disease lack enough evidence for casual supplementation.

Tolerance, Cycling, Product Quality, and Monitoring

PQQ is not known to cause classic dependence or withdrawal. Human tolerance data are limited, and no evidence-based cycling schedule exists. A one-week washout should remove parent-drug exposure, while a longer period may be needed to judge whether a subtle sustained effect truly disappears.

Use a verified PQQ disodium-salt product with identity, dose, heavy-metal, and microbial testing. “PQQ” on a label does not prove the exact salt or the claimed milligrams.

Track sleep, anxiety, resting energy, and a repeatable cognitive outcome across several weeks. If it feels energizing but sleep worsens, the next-day deficit can erase the apparent gain. If neither subjective function nor objective output changes, a mitochondrial story alone is not a reason to continue.

Bottom Line

PQQ is a plausible slow mitochondrial signaling supplement with a few encouraging but modest human trials. The realistic expectation is either no obvious effect or a gradual reduction in background fatigue—not instant fuel, a stimulant high, or proven intelligence enhancement.

18.6 NAD Precursors and NAD Delivery​

NAD accepts and donates electrons during fuel metabolism and is consumed by repair and signaling enzymes. Blood target engagement is measurable, but the guide separates that from cellular, mitochondrial, brain, and cognitive outcomes.

18.6.1 Nicotinamide Riboside (NR) — A Measurable NAD Precursor With Conditional Benefits

What it is: Nicotinamide riboside is a water-soluble vitamin-B3-family nucleoside, usually supplied as stabilized NR chloride. Cells convert it through NMN into NAD+, a molecule required for energy transfer, DNA repair, and signaling.

What it may feel like: Most healthy users feel nothing acute. Some older or fatigued users describe cleaner background energy, sharper thinking, better exercise tolerance, or greater motivation after days or weeks; others report insomnia, anxiety, headache, or complete nonresponse. It should not feel like a conventional stimulant.

The simplest description: NR supplies more raw material to the NAD salvage factory. It can raise blood NAD, but extra raw material only improves performance when NAD availability was actually limiting the system.

How It Works

NR enters the NAD salvage pathway through nicotinamide-riboside kinases, becoming NMN and then NAD+. NAD+ accepts electrons during metabolism and is consumed by enzymes including sirtuins, PARPs, and CD38. Raising its availability may matter with aging, inflammation, metabolic disease, or other states of accelerated NAD consumption.

The common marketing error is to equate “blood NAD increased” with “brain energy and intelligence increased.” Blood target engagement proves that the precursor entered human metabolism; it does not prove that neuronal NAD was deficient or that cognition improved.

Dose and How It Is Taken

Human trials commonly use 300–1,000 mg/day of NR chloride, with studies ranging from 100 mg/day to 2,000 mg/day. These are studied exposures, not evidence that the top dose is superior. A practical research trial normally begins with the lowest relevant studied amount rather than treating a larger NAD rise as the objective.

NR is water-soluble and does not require fat. It may be taken with or without food; breakfast is practical because food can reduce nausea and morning dosing limits personally activating effects on sleep. NR chloride mass is not identical to elemental NR mass, so labels must state what the milligrams represent.

Timing and Pharmacokinetics

• Subjective onset: Usually absent; anecdotes range from a few hours to several weeks.
• NR Tmax: Roughly three hours in a small human PK study.
• Parent NR half-life: Short and variable; approximately 2.7 hours has been reported.
• Blood-NAD response: Can rise after a single dose and remains elevated more smoothly than parent NR concentration.
• Accumulation/full effect: Blood NAD generally rises across days and can take roughly two weeks to stabilize in small newer PK work; functional outcomes are commonly judged after 4–12 weeks.
• Near-complete elimination: Parent NR clears within roughly a day, while the expanded NAD metabolome normalizes more slowly and does not have one universally established washout.

Absolute oral bioavailability of intact NR is not known cleanly because part is converted in the gut and liver to nicotinamide and other metabolites before tissues rebuild NAD. That still represents biological availability, but it is not proof that intact NR reaches every target organ. Excess nitrogenous metabolites are methylated and excreted through urine. Human NR PK study, dose-response trial

• Absorption/bioavailability: Oral NR is absorbed and extensively converted through nicotinamide and other NAD-metabolome intermediates; a simple intact-parent percentage is not the useful exposure measure.
• Full practical effect: Blood NAD can change quickly, but functional outcomes are usually judged after 4–12 weeks.
• Subjective duration: Usually no clean acute window; reported energy or sleep changes may last through the day.
• Half-life: Parent NR is short-lived and variable; approximately 2.7 hours has been reported.
• Accumulation/steady state: Parent NR does not meaningfully accumulate, while blood NAD-related pools can rise across roughly two weeks.
• Metabolism/elimination: NR enters the NAD salvage network, is converted to nicotinamide-related metabolites, and excess material is methylated and excreted in urine.

Evidence and Experiences

Repeated trials show that NR can raise the blood NAD metabolome and is generally tolerated over weeks to months. Clinical outcomes are less consistent: selected vascular, inflammatory, neurological, metabolic, or exercise signals appear in some populations, while many trials find target engagement without meaningful functional improvement.

Healthy-young-adult cognitive evidence is weak. A user report of more energy and sharper conversation after several days is vivid but was also produced by a stack containing resveratrol, quercetin, and fisetin, so NR cannot be isolated. Sleep reduction is also not automatically a benefit; losing restorative sleep can erase any daytime gain. Representative experience

Safety, Interactions, and Monitoring

Reported effects include nausea, gastrointestinal upset, headache, fatigue, flushing-like warmth, activation, and sleep disruption. Larger chronic NAD-precursor loads increase nicotinamide turnover and methylated metabolites; the clinical importance of this in healthy users remains unsettled.

Serious liver or kidney disease, pregnancy, breastfeeding, active cancer treatment, and complex metabolic medication deserve clinician review. Claims that NR necessarily accelerates cancer are not established, but NAD biology supports both healthy-cell function and tumor-cell metabolism, so active cancer is not a casual self-experiment.

Classic dependence and withdrawal are not expected, and no evidence-based cycling rule exists. Track sleep, resting heart rate, blood pressure when relevant, fatigue, exercise or cognitive output, and clinically appropriate liver, kidney, glucose, or lipid measures. Choose a verified NR-chloride product with batch identity and potency testing; degradation and under-dosing make results uninterpretable.

Bottom Line

NR reliably enters human NAD metabolism, but the felt and functional payoff depends on baseline age, illness, and metabolic demand. It is a slow metabolic precursor—not an instant focus drug—and a higher NAD number is not itself a nootropic outcome.

18.6.2 Nicotinamide Mononucleotide (NMN) — One Step Closer to NAD, Not Automatically Better

What it is: Beta-nicotinamide mononucleotide is a water-soluble nucleotide directly upstream of NAD+. Oral NMN may be absorbed, dephosphorylated to NR, or converted through gut and liver pathways before its atoms appear in NAD.

What it may feel like: The modal experience is subtle or nothing. Responders describe broad, calm energy, easier exercise, or clearer focus rather than caffeine-like pressure. A minority report a pronounced surge, racing heart, dizziness, insomnia, or an initial good period followed by fatigue.

The simplest description: NMN delivers NAD-building material one biochemical step closer to the final product, but the digestive system can take that material apart and rebuild it. “Closer on a pathway diagram” does not guarantee better delivery to the brain.

How It Works

NMN is converted to NAD+ by NMN adenylyltransferases. NAD+ then supports redox energy transfer and enzymes involved in repair, stress signaling, and gene regulation. Oral human studies generally find higher blood NAD or downstream metabolites, although intact plasma NMN does not rise consistently.

This is a supply-side intervention. It may help when age or disease has lowered NAD availability; it will not correct sleep deprivation, iron deficiency, hypothyroidism, inadequate calories, or a damaged cardiovascular system simply because all of those problems eventually touch metabolism.

Dose and How It Is Taken

Common human trials use 250–300 mg once daily, while dose-ranging studies have used 300, 600, or 900 mg/day for roughly two months. A 2026 EFSA assessment considered a proposed supplement maximum of 300 mg/day for adults; jurisdictional regulatory status can change and should be checked where the reader lives.

NMN is water-soluble and does not need dietary fat. Morning oral dosing with or without breakfast is the most defensible practical route. Food can reduce stomach discomfort, and there is no good evidence that an empty stomach, liposomal formulation, or holding powder under the tongue reliably produces superior brain delivery. A 2026 crossover study found different early metabolites after sublingual administration, but this is not the same as proven superior outcomes.

Timing and Pharmacokinetics

• Subjective onset: Commonly absent; anecdotes range from hours to several weeks.
• Parent NMN Tmax/half-life: No single reliable human value is established because intact NMN is transient and studies often detect metabolites rather than parent compound.
• Metabolic onset: Downstream NAD metabolites can change within hours after an oral dose.
• Accumulation/steady state: Blood NAD changes develop over days; small precursor studies suggest roughly two weeks to a plateau.
• Full practical effect: Human functional trials usually assess 6–12 weeks.
• Near-complete elimination: Intact parent exposure is brief, but expanded blood NAD and downstream signaling normalize across days rather than on the parent-molecule clock; no universal washout is validated.

Absolute bioavailability of intact NMN is unresolved. Human studies show increases in NAMN, nicotinamide catabolites, and blood NAD even when plasma NMN itself does not rise, indicating substantial processing before or during uptake. Controlled metabolism study, older-men trial

• Absorption/bioavailability: Oral exposure is demonstrated, but intact NMN versus dephosphorylated NR and downstream metabolites cannot be summarized by one settled human percentage.
• Subjective duration: Usually no distinct acute window; occasional activation or insomnia may occupy the dosing day.
• Half-life: No dependable single human parent-NMN half-life is established because intact exposure is transient and assays often emphasize metabolites.
• Metabolism/elimination: NMN enters NAD salvage directly or after dephosphorylation, with excess nicotinamide-related metabolites ultimately cleared in urine.

Evidence and Experiences

Trials in middle-aged or older adults report reliable NAD target engagement and occasional improvements in insulin sensitivity, walking or muscle outcomes, aerobic capacity, or selected aging measures. Samples are small to moderate, follow-up is short, products and assays differ, and dramatic lifespan claims remain extrapolated from animals.

Evidence for improving cognition in healthy teenagers or young adults is inadequate. Online users describe both relaxed energy and striking activation, but also dizziness, poor sleep, racing heart, and delayed fatigue. These experiences are not incidence data and may reflect products, expectations, age, stacks, or underlying illness. Energy discussion, adverse and nonresponse discussion

Safety, Interactions, and Monitoring

Short trials generally find good tolerability. Possible complaints include gastrointestinal upset, headache, dizziness, fatigue, activation, insomnia, and palpitations. Stop for persistent tachycardia, fainting, severe dizziness, allergic reaction, jaundice, or a major change in cognition or mood.

Pregnancy, breastfeeding, childhood, serious liver or kidney disease, and active cancer treatment lack sufficient evidence for casual use. Interaction trials are sparse, so combinations with glucose-lowering medication or multiple NAD agents deserve monitoring rather than assuming biochemical compatibility.

Classic dependence is not expected, and cycling has not been shown necessary. Track sleep duration and quality, resting heart rate, blood pressure, exercise or cognitive output, and clinically relevant glucose, liver, or kidney measures. Use verified beta-NMN with identity, purity, stability, and batch-potency testing; NAD products have a documented quality-control problem.

Tolerance is not established as a classic psychoactive process, and no evidence-based cycling schedule exists.

Bottom Line

NMN can raise the human NAD metabolome, but “one step closer” does not make it a proven superior nootropic. The realistic outcome is either no felt effect or gradual background energy in a responder, with particular caution for insomnia and activation.

18.6.3 5-Amino-1MQ — An NNMT Research Chemical Without Human Dosing Science

What it is: 5-amino-1-methylquinolinium, usually discussed as an iodide salt, is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It is frequently marketed beside peptides, but it is not a peptide and has no established human indication.

What it may feel like: No trustworthy human signature exists. Gray-market reports describe a subtle non-stimulant leaning-out effect, steadier energy during calorie restriction, or nothing at all; others report emotional blunting, urinary symptoms, or suspected mislabeled product. Because identity was rarely verified, these are reports about purchased vials or capsules, not clean observations of 5-amino-1MQ.

The simplest description: NNMT spends nicotinamide and a methyl group. Blocking it may preserve NAD-building material and alter fat-cell metabolism—but in humans this remains an animal-derived hypothesis, not a finished drug.

How It Works

NNMT transfers a methyl group from SAM to nicotinamide, producing methyl-nicotinamide. In animal adipose research, inhibiting NNMT changes NAD and methyl-donor balance, energy expenditure, and fat accumulation. This makes the target interesting for obesity and metabolic disease.

The same mechanism creates uncertainty. Methylation and nicotinamide disposal are integrated with many pathways; blocking an enzyme is not automatically “saving NAD” without tradeoffs. Brain penetration, central selectivity, useful exposure, and long-term consequences in humans are not established.

Dose and How It Is Taken

No validated human dose exists. Online protocols commonly report approximately 25–100 mg/day orally or unvalidated injected amounts. These anecdotes cannot establish bioavailability, safety, or a starting dose and should not be presented as clinical guidance.

Public human values for oral or injected bioavailability, subjective onset, pharmacologic onset, Tmax, half-life, steady state, active metabolites, and complete elimination are missing. Claims that it works within hours or should be cycled for four weeks come from vendors and self-experimenters, not human PK trials.

Solubility depends on the exact salt; laboratory salts may be water-compatible, but solubility does not make a material sterile, injectable, or safe to swallow. Injecting research powder introduces additional contamination, endotoxin, pH, osmolarity, and sterility hazards.

Timing and Pharmacokinetics

• Subjective onset: Unknown; gray-market anecdotes range from same-day change to no effect.
• Absorption/bioavailability: Unknown in humans for oral or injected routes.
• Tmax: Unknown in humans.
• Full practical effect: Unknown; animal body-composition experiments cannot supply a human clock.
• Subjective duration: Unknown.
• Half-life: Unknown in humans.
• Accumulation/steady state: Unknown in humans.
• Near-complete elimination: Cannot be calculated without human PK.
• Metabolism/elimination: Human enzymes, metabolites, and excretion fractions are unknown.

Evidence and Experiences

The evidence base is preclinical: cell and rodent studies support NNMT as a metabolic target, but no published human Phase I dose-escalation, modern PK study, or placebo-controlled efficacy trial establishes 5-amino-1MQ as of this review.

A detailed online report described 50 mg/day orally for a month as non-stimulating, with subtle body-composition changes after two to three weeks and emotional dulling at higher exposure. Another user developed marked urination and pelvic tension after a supposed product and questioned whether it was authentic. The contradiction is the lesson: without analytical identity and controlled humans, “experience” may reflect the molecule, a contaminant, a substitute, diet, or expectation. Subtle-use report, suspected-product warning

Safety, Interactions, and Monitoring

Human adverse-effect incidence, organ toxicity, reproductive toxicity, drug interactions, tolerance, dependence, and withdrawal are unknown. The absence of reported disaster in a small online community is not a safety study.

Avoid unsupervised use in minors, pregnancy, breastfeeding, active cancer, serious liver or kidney disease, unstable psychiatric illness, or alongside complex metabolic and methylation interventions. Stop and seek care for severe urinary changes, jaundice, persistent vomiting, chest pain, fainting, neurological changes, allergic symptoms, or marked mood deterioration.

There is no evidence-based cycling or washout period. Product identity requires third-party methods capable of confirming molecular identity and quantity—not a vendor PDF that says only “purity.” Injectable use additionally requires sterility and endotoxin testing that ordinary HPLC does not provide.

Bottom Line

5-amino-1MQ is an interesting NNMT laboratory tool with essentially no human dosing or PK foundation. Its entry belongs in the guide to explain the target and the uncertainty, not to convert vendor protocols into a teenage fat-loss or nootropic regimen.

18.6.4 Intravenous or Injected NAD+ — Direct Delivery, Indirect Biology

What it is: NAD+ infusion places oxidized nicotinamide adenine dinucleotide directly into the bloodstream. It bypasses intestinal absorption but does not mean intact NAD+ instantly enters neurons; extracellular NAD is extensively broken into smaller metabolites before tissues reuse it.

What it may feel like: Slow infusions are often described as neutral or mildly energizing afterward. During faster infusion, chest tightness, abdominal cramping, nausea, headache, warmth, pressure in the head or ears, diarrhea, muscle tightness, weakness, and wooziness are recurring reports. These acute sensations are infusion intolerance—not proof that NAD is “flooding the mitochondria.”

The simplest description: IV NAD puts the finished molecule into blood, but cell membranes and enzymes still decide how its pieces are processed and rebuilt. Skipping the gut does not skip biology.

How It Works

Extracellular enzymes including CD38 and related nucleotidases break NAD+ into NMN, NR, nicotinamide, and other metabolites. Those components can enter salvage pathways and influence the circulating NAD metabolome. Intact NAD may also signal through purinergic and immune pathways.

In a small six-hour human infusion study, plasma NAD did not simply rise in proportion to delivery during the first two hours; metabolites rose as infused NAD was rapidly cleared and processed. This is incompatible with the clinic slogan that the drip directly fills every cell with intact NAD. Six-hour metabolism study

Dose and How It Is Taken

Published pilot work has infused approximately 750 mg over six hours or 500 mg under monitored protocols. These are research exposures, not a self-injection guide. IV administration requires a licensed clinical setting, verified sterile pharmaceutical material, line safety, and continuous response to infusion symptoms.

Timing and Pharmacokinetics

• Subjective onset: Symptoms can appear during the infusion; claimed energy benefits range from later that day to several days.
• Systemic onset: Immediate entry into blood.
• Tmax: During or at the end of infusion for delivered material, while metabolites follow different clocks.
• Half-life: A useful human terminal half-life for intact infused NAD+ has not been firmly established because extracellular metabolism is rapid and assays measure different pools.
• Full effect/accumulation: No validated schedule or time to full nootropic effect exists.
• Near-complete elimination: Unknown for the total metabolomic perturbation; clinic claims of a fixed multi-day “recharge” are not validated PK.

NAD+ is highly water-soluble. This makes aqueous infusion possible, but says nothing about sterility, stability, compatibility, or infusion rate. Intramuscular or subcutaneous “NAD injections” cannot inherit IV research because route changes the concentration, tissue exposure, pain, and contamination risk.

• Absorption/bioavailability: Intravenous delivery makes bloodstream availability immediate, but intact cellular and brain bioavailability remains limited by extracellular cleavage and membrane transport.
• Full practical effect: No validated time to maximal nootropic benefit exists; acute intolerance occurs during infusion, while claimed energy effects are judged later.
• Subjective duration: Infusion symptoms usually track the administration period; claimed after-effects range from hours to days without controlled confirmation.
• Accumulation/steady state: No validated repeated-infusion steady state exists for intact NAD or the broader metabolomic response.
• Metabolism/elimination: Extracellular enzymes rapidly cleave NAD into reusable precursors and metabolites, which enter ordinary salvage pathways and renal or biliary clearance.

Evidence and Experiences

Human evidence consists mostly of small metabolism, tolerability, and pilot studies. There is not a robust placebo-controlled program showing durable cognition, anti-aging, addiction recovery, or athletic enhancement in healthy adults.

A randomized pilot comparing oral NR, IV NR, and IV NAD found more infusion-related symptoms with NAD+ and a stronger three-hour blood-NAD rise with IV NR; the report began as a preprint and requires replication. The vivid takeaway is practical: direct NAD was not automatically the cleanest or most effective way to raise the measured blood pool. Pilot comparison

Safety, Interactions, and Monitoring

Rate-dependent nausea, abdominal or muscle cramping, diarrhea, headache, chest or head pressure, flushing, and weakness are common enough to plan for. Any IV also carries infection, phlebitis, infiltration, dosing-error, and allergic risks. Slowing the infusion may reduce ordinary symptoms, but chest pain, breathing difficulty, fainting, neurological change, severe vomiting, fever, or a line-site infection requires immediate clinical assessment.

Pregnancy, breastfeeding, minors, serious cardiovascular disease, kidney or liver disease, active cancer, and complex medication require specialist review. Unlicensed home infusion and reconstituting gray-market powder are unjustifiable.

There is no demonstrated dependence or standard cycling requirement, but repeated-clinic schedules are marketing conventions rather than outcome-validated protocols. Monitor vital signs during administration, CBC/CMP when clinically indicated, glucose, sleep, fatigue, and a predefined functional outcome. Cost must include professional administration and risk, not just milligrams.

Product and clinic quality are inseparable from risk: sterile compounding, identity, concentration, endotoxin control, line care, infusion rate, and emergency capability matter more than a wellness label.

Bottom Line

IV NAD guarantees blood delivery, not direct neuronal delivery or proven cognitive enhancement. Its human evidence remains small, infusion intolerance is common, and oral precursors are cheaper and better studied. It belongs under supervised experimental medicine, not routine supplement practice.

18.7 Ketone Precursors​

Ketones can be swallowed directly, generated from a precursor, or produced by the liver during carbohydrate restriction. These routes produce different stereochemistry, mineral load, kinetics, calories, and systemic effects. The brain can oxidize ketones, especially during sustained ketosis, but ketones do not replace oxygen or functioning mitochondria.

18.7.1 R-1,3-Butanediol — A Ketone Precursor With Alcohol-Like Cautions

What it is: R-1,3-butanediol is a chiral diol that the liver oxidizes through alcohol and aldehyde dehydrogenase into R-BHB. It is also the alcohol component released from several ketone esters.

What it may feel like: At modest studied beverage amounts, many people report little beyond reduced sleepiness or smooth energy. Others describe a mild alcohol-like state, headache, nausea, or no “buzz” at all. A compound marketed as “ketohol” should be treated as potentially impairing until reaction time and coordination are proven normal.

The simplest description: R-1,3-butanediol asks the liver to turn an alcohol-like molecule into ketone fuel. This produces a slower ketone curve than swallowing BHB directly and also occupies hepatic alcohol metabolism.

How It Works

Alcohol dehydrogenase oxidizes R-1,3-butanediol through intermediates into R-BHB, which then circulates as fuel and signal. The R stereochemistry matters; other butanediol isomers do not share the same metabolic and safety profile.

Dose and How It Is Taken

A short human study tested three 11.5-gram servings in one day, while commercial beverages often provide roughly 10–17 grams per serving. These are studied or marketed exposures, not proof of an optimal nootropic dose.

R-1,3-butanediol is water-miscible and can be formulated in beverages. It does not require fat. Food may blunt and smooth the ketone curve and reduce nausea; alcohol should not be combined because the same liver enzyme system and impairment risk are involved.

Timing and Pharmacokinetics

• Subjective onset: Approximately 30–90 minutes.
• BHB onset/Tmax: BHB rises within the first hour and commonly peaks across approximately 1–3 hours.
• Subjective duration: Elevated ketones can last several hours, often longer and lower than an ester peak.
• Parent half-life/bioavailability: Modern human values are not adequately established; rapid hepatic conversion makes BHB the practical exposure marker.
• Accumulation/steady state: Repeated servings create overlapping ketone and parent exposure; safe chronic accumulation is insufficiently characterized.
• Near-complete elimination: A single serving’s ketone effect generally recedes the same day, but an exact parent washout is not validated.

Acute human tolerability study

• Absorption/bioavailability: Oral absorption and hepatic conversion are established, but a dependable absolute parent percentage is not adequately public.
• Full practical effect: The ketone effect is generally strongest across the first few hours, while impairment or nausea may define the practical limit.
• Half-life: A dependable modern human parent half-life is not established; BHB is the more useful measured exposure.
• Metabolism/elimination: Alcohol and aldehyde dehydrogenases convert R-1,3-butanediol toward R-BHB, which tissues oxidize as fuel.

Evidence and Experiences

Human evidence mainly demonstrates ketone production and short-term tolerability, not improved grades, intelligence, or long-term brain health. Effects on sleepiness are exploratory. Anecdotes range from no buzz to an alcohol-like feeling and severe headache/nausea, which makes driving and high-stakes activity inappropriate on a first trial. User-experience discussion

R-1,3-butanediol is structurally distinct from GHB and is intended to become BHB, not GHB. Similar-sounding chemistry should not be used to promise GHB-like sleep or mood effects.

Safety, Interactions, and Monitoring

Nausea, headache, gastrointestinal upset, dizziness, taste aversion, and possible psychomotor impairment are the practical concerns. Do not combine with alcohol, sedatives, driving, or other ketone products until total exposure is understood.

Liver disease, pregnancy, breastfeeding, minors, diabetes medication, SGLT2 inhibitors, and alcohol-use disorder require avoidance or medical review. Stop for confusion, loss of coordination, persistent vomiting, severe abdominal pain, fainting, or signs of ketoacidosis.

No evidence-based cycling schedule exists, and dependence research is inadequate. Track BHB, glucose when relevant, reaction time, balance, subjective impairment, sleep, gastrointestinal effects, and the exact R-isomer dose. Product identity and stereochemical testing are essential.

Tolerance, dependence, and chronic adaptation are insufficiently characterized; alcohol-like subjective effects make escalation and driving especially poor experiments.

Bottom Line

R-1,3-butanediol is a slower ketone prodrug with emerging human tolerability data and little cognitive-efficacy evidence. Its practical value is temporary alternative fuel; its alcohol-like metabolism and possible impairment make casual “ketohol” framing irresponsible.

18.8 Mitochondrial-Derived Peptides​

MOTS-c and humanin are short messages encoded within mitochondrial genetic regions. They are signaling hypotheses, not metabolic fuels. Endogenous associations and animal administration must be separated from safe, effective human dosing.

18.8.1 MOTS-c — An Exercise Signal, Not Exercise in a Vial

What it is: MOTS-c is a 16-amino-acid peptide encoded within mitochondrial 12S rRNA. Human muscle and blood levels respond to exercise, while injected MOTS-c has mostly been studied in cells and animals. The clinical candidate CB4211 is a modified analog, not proof that gray-market native MOTS-c has the same PK or safety.

What it may feel like: There is no validated human signature. Self-experimenters describe improved endurance, easier recovery, steadier glucose, fatigue, headache, or no effect. When a positive effect is reported, it is most visible during a workout or prolonged demand: the person realizes late in the session that the usual collapse did not arrive as quickly. At rest, it may be imperceptible.

The simplest description: MOTS-c appears to be one of the messages mitochondria and muscle use to announce energetic stress and coordinate adaptation. Injecting the message is not equivalent to reproducing all of exercise.

How It Works

Under metabolic stress, MOTS-c can move into the nucleus and influence stress-response genes through AMPK-related pathways. Animal work suggests improved glucose uptake, insulin sensitivity, mitochondrial adaptation, and physical capacity.

In healthy men, an exercise bout increased endogenous MOTS-c in muscle approximately twelvefold and circulating levels about 1.5-fold before plasma returned toward baseline over four hours. This proves that MOTS-c participates in human exercise biology; it does not prove that an injected commercial vial improves human performance. Exercise-induced human data

Dose and How It Is Taken

There is no validated human dose for native MOTS-c. Online protocols commonly discuss milligram subcutaneous injections, but no published human PK program establishes their dose, onset, Tmax, half-life, accumulation, full effect, or washout.

CB4211 underwent early clinical testing in healthy adults and people with metabolic disease, but analog doses cannot be transferred molecule-for-molecule to native MOTS-c. The public literature does not provide enough independently reviewed detail to turn that program into a consumer schedule.

MOTS-c is a water-compatible peptide that would be destroyed or poorly absorbed when simply swallowed. This does not make research powder injectable. Sterility, endotoxin, aggregation, sequence identity, pH, and concentration are separate requirements.

Solubility and practical administration: MOTS-c is a peptide whose aqueous solubility depends on sequence, counterion, concentration, pH, and excipients. A powder dissolving in water does not prove identity, stability, sterility, or safe injection, and there is no validated consumer formulation or oral-empty-stomach rule.

Timing and Pharmacokinetics

• Anecdotal subjective onset: Same day to several weeks.
• Expected parent-peptide onset: Rapid after injection, but not quantified in humans.
• Tmax/half-life/bioavailability: Unknown for native human use.
• Full practical effect: Animal adaptation and online protocols span days to weeks; no validated human clock exists.
• Near-complete elimination: Unknown; downstream gene expression may outlast the circulating peptide.
• Subjective onset: Anecdotes range from the same day to several weeks, but there is no validated human cue.
• Absorption/bioavailability: Native oral exposure is expected to be poor; injected human absolute bioavailability and BBB delivery are unknown.
• Subjective duration: Unknown; reports describe exercise-session or day-level changes without verified exposure.
• Half-life: Unknown in humans for native MOTS-c.
• Accumulation/steady state: Unknown; downstream gene expression could outlast the parent peptide without chemical accumulation.
• Metabolism/elimination: Expected peptidase cleavage and ordinary amino-acid handling, but no human mass-balance study exists.

Evidence and Experiences

The biological evidence is strong enough to make MOTS-c scientifically important: exercise changes endogenous human MOTS-c, human genetic variation relates to metabolic phenotypes, and animal administration alters performance and glucose regulation. Actual enhancement evidence from administered native peptide in humans remains absent.

Forum reports are sparse, product identity is rarely verified, and fatigue is reported as well as endurance. That means phenomenology can be described only as a possibility, not a prediction. Mixed fatigue discussion, dose-and-evidence discussion

Safety, Interactions, and Monitoring

Human adverse-effect incidence, immunogenicity, reproductive safety, cancer implications, drug interactions, and organ toxicity are unknown for native injected MOTS-c. AMPK and glucose effects create plausible interactions with fasting, diabetes medication, metformin, and hard training. “Naturally encoded” does not mean a pharmacological injection is physiologically natural.

Avoid unsupervised use in minors, pregnancy, breastfeeding, active cancer, diabetes medication, immune disease, or serious liver and kidney disease. Stop for allergic symptoms, persistent tachycardia, severe weakness, hypoglycemic symptoms, infection, neurological change, or significant exercise intolerance.

No evidence-based cycle exists. Monitoring would require authenticated material, glucose, resting vitals, training output, recovery, sleep, injection sites, and appropriate labs. Exercise already raises endogenous MOTS-c and has vastly stronger outcome evidence.

Bottom Line

MOTS-c is a compelling exercise-responsive mitochondrial signal with inadequate administered-human evidence. It may eventually become a metabolic therapy; today, native gray-market injection remains an unvalidated experiment whose dose and PK are unknown.

18.8.2 Humanin — A Cellular Distress Signal With No Established Human Treatment

What it is: Humanin is a 24-amino-acid mitochondrial-derived peptide associated with cell-survival signaling. HNG, or S14G-humanin, is a much more potent synthetic analog in many laboratory assays and must not be treated as equivalent to native humanin.

What it may feel like: No repeatable controlled-human phenomenology exists. Sparse self-reports range from unusually pleasant calm, clearer cognition, or better energy to no effect; doses and identities are rarely verified. Humanin is better understood as a putative cytoprotective signal than as something expected to “hit.”

The simplest description: Humanin acts like an intracellular distress message telling vulnerable cells to resist inappropriate shutdown. Preventing unnecessary cell death may be useful in disease, but indiscriminately protecting cells can also be undesirable.

How It Works

Humanin interacts with intracellular death machinery including Bax and IGFBP-3 and with cell-surface receptor systems that activate survival pathways. Preclinical work reports neuroprotective, insulin-sensitizing, cardiovascular, and anti-inflammatory effects.

The vivid image is a building’s emergency controller refusing to demolish a damaged room while repairs are still possible. That is beneficial when a neuron is being pushed toward death by temporary stress. It may be harmful when the “room” is a malignant or irreparably damaged cell that should be removed.

Dose and How It Is Taken

There is no established human dose for native humanin or HNG. Online microgram regimens are extrapolated from animals and vendors, not Phase I trials.

• Absorption/bioavailability: Oral peptide bioavailability is expected to be poor; injected human bioavailability is unmeasured.

Timing and Pharmacokinetics

• Subjective and pharmacologic onset: Unknown in humans.
• Tmax, half-life, duration, accumulation, and elimination: Unknown for humans.
• Rodent reference: Native and analog peptides clear rapidly and distribute differently, but animal PK cannot supply a human schedule.
• Full practical effect: No validated human endpoint or clock exists.

Humanin is water-compatible as a peptide, but research solubility does not establish sterility, endotoxin control, correct folding, or suitability for injection. Rodent PK study

• Subjective onset: Unknown in humans.
• Subjective duration: Unknown because no reproducible controlled-human experience exists.
• Half-life: Unknown in humans for native humanin and its analogues.
• Accumulation/steady state: Unknown; analogues cannot inherit native-peptide assumptions.
• Near-complete elimination: Cannot be calculated without human PK.
• Metabolism/elimination: Expected peptidase cleavage, receptor-mediated uptake, and amino-acid handling; human mass balance is unavailable.

Evidence and Experiences

Human exercise studies show endogenous humanin changes in muscle or plasma, and observational work links levels with aging and metabolic states. Administered efficacy remains preclinical: cell, rodent, and mechanistic research dominate, with no well-controlled therapeutic human trials.

Reddit discussions contain far more requests for dosing than reproducible experiences. One striking “best feeling” report exists alongside many threads with no substantive follow-up, exactly the pattern in which publication and expectation bias dominate. Sparse experience thread, older subjective report

Safety, Interactions, and Monitoring

Human safety incidence, immunogenicity, reproductive toxicity, and interactions are unknown. Cytoprotection and insulin signaling create theoretical concerns in active cancer, chemotherapy, diabetes medication, and abnormal-cell survival. Experimental breast-cancer models have reported tumor-promoting effects under some conditions; this is not proof of human cancer causation, but it defeats the claim that more humanin is automatically beneficial.

Avoid unsupervised use in minors, pregnancy, breastfeeding, active or recent cancer, diabetes medication, immune disease, and serious organ disease. Stop for allergic symptoms, hypoglycemia, infection, new mass or unexplained systemic symptoms, or significant neurological deterioration.

There is no evidence-based cycling or washout. A real study would require verified sequence and analog, sterile/endotoxin-tested formulation, PK sampling, antibodies, glucose, IGF-axis measures, organ labs, and predefined functional outcomes.

Human tolerance, dependence, withdrawal, cycling, and interaction washout are unknown.

Bottom Line

Humanin is an important mitochondrial survival peptide and a poor candidate for confident self-dosing. The mechanism is promising precisely because it changes whether stressed cells live or die; that same power makes missing human safety and cancer-context data impossible to ignore.

18.9 Mitochondria-Targeted Membrane Peptides​

Elamipretide targets cardiolipin-related inner-membrane biology. It is structurally and conceptually distinct from peptides encoded by mitochondrial DNA.

18.9.1 Elamipretide (SS-31; Forzinity) — Mitochondrial Membrane Repair With a Real Drug Label

What it is: Elamipretide is a water-soluble four-amino-acid mitochondrial peptide that binds cardiolipin in the inner mitochondrial membrane. In 2025, the FDA granted accelerated approval as Forzinity to improve muscle strength in Barth syndrome patients weighing at least 30 kg.

What it may feel like: It is not expected to “kick in” like caffeine. Some symptomatic users describe realizing after days that they can remain active or think for longer without the usual fatigue; others report immediate energy, flat mood, tiredness, or no benefit. Injection-site redness and pain are far more dependable than a nootropic sensation.

The simplest description: Cardiolipin organizes the inner mitochondrial membrane where the respiratory chain works. Elamipretide acts less like adding fuel and more like stabilizing the workbench so the existing machinery leaks less and holds its shape.

How It Works

Elamipretide localizes to the inner mitochondrial membrane and binds cardiolipin, supporting membrane curvature, cristae structure, respiratory-chain organization, and redox efficiency. This is most compelling in Barth syndrome, where cardiolipin remodeling is genetically defective.

That disease context matters. Repairing a structurally abnormal mitochondrial membrane can improve muscle strength without implying that a healthy membrane becomes superhuman.

Dose and How It Is Taken

Approved Barth-syndrome dose: 40 mg subcutaneously once daily for patients at least 30 kg; adults with severe renal impairment who are not on dialysis receive 20 mg. This is a prescription disease dose, not a longevity or student recommendation.

Forzinity is a sterile 80 mg/mL aqueous product. The peptide is freely water-soluble, but an online lyophilized vial cannot inherit its sterility, preservative system, concentration, stability, or authorization.

Timing and Pharmacokinetics

• Subjective onset: Variable; same day to several weeks, with many nonresponders.
• Pharmacologic onset: Begins after subcutaneous absorption.
• Tmax: 0.5–1 hour.
• Absorption/bioavailability: Approximately 92%.
• Dose proportionality: Exposure is proportional across 2–80 mg daily.
• Accumulation/steady state: Minimal with once-daily dosing.
• Half-life: The public label does not present one simple terminal value suitable for consumer timing.
• Metabolism/elimination: Sequential C-terminal cleavage produces inactive M1 tripeptide and M2 dipeptide.
• Near-complete elimination: In normal renal function, approximately 100% of dose-related material was recovered in urine as parent, M1, or M2 by 48 hours.
• Full practical effect: Barth outcomes developed during weeks to months; Tmax is not the time to maximal structural or functional benefit.

FDA prescribing information

• Subjective duration: Acute sensations may occupy the injection day; disease-related functional outcomes are evaluated across weeks or months.

Evidence and Experiences

The strongest evidence belongs to a tiny, genetically defined Barth-syndrome population and an intermediate muscle-strength endpoint, with confirmatory benefit still required under accelerated approval. Trials in primary mitochondrial myopathy, heart disease, eye disease, and aging-related endpoints have produced mixed results.

Reddit reports describe both “able to go all day without fatigue” and fatigue/flat mood. They are drawn largely from ME/CFS and peptide communities using unverified products and stacks, so they illustrate possibilities rather than incidence. Mixed experience thread, ME/CFS experience report

Safety, Interactions, and Monitoring

Injection-site erythema occurred in all 12 patients in the pivotal safety population, with pain, induration, itching, bruising, and urticaria also common. Serious hypersensitivity can occur minutes to months after starting. Exposure rises substantially with renal impairment, requiring approved dose modification.

Stop and seek urgent care for breathing difficulty, facial swelling, generalized hives, fainting, or severe systemic reaction. Pregnancy data are limited; neonates must not receive the benzyl-alcohol-containing product. Gray-market injection adds infection and endotoxin risks absent from the drug label.

Classic dependence and withdrawal are not expected, but no healthy-user cycling protocol exists. Monitor renal function, injection sites, allergy, muscle strength, exercise capacity, fatigue, sleep, and the disease-specific target. Use only a prescribed authenticated product.

Classic dependence is not expected, but pharmacodynamic adaptation and tolerance have not been characterized as a healthy-use strategy; no evidence-based cycling rule exists.

Bottom Line

Elamipretide is no longer merely a research peptide: it is a narrowly approved mitochondrial drug with defined subcutaneous PK. Its real indication strengthens the cardiolipin mechanism while simultaneously showing why healthy “mitochondrial optimization” cannot borrow a rare-disease dose or promise.

18.10 Experimental Exercise Mimetics​

Exercise changes blood flow, mechanical load, temperature, calcium, hormones, neurotransmission, mitochondria, bone, muscle, and behavior. A molecule that reproduces one transcriptional program is not exercise in a capsule.

18.10.1 SLU-PP-332 — A Mouse Exercise-Mimetic Probe, Not a Human Protocol

What it is: SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors ERRα, ERRβ, and ERRγ, with the strongest activity at ERRα. Despite being sold by peptide vendors, it is not a peptide, estrogen, SARM, or approved drug.

What it may feel like: No controlled human experience exists. Online reports range from no effect to claimed endurance or fat-loss changes, but products, routes, and identities are unverified. The honest expectation is unknown—not “cardio in a vial.”

The simplest description: ERRs help write the genetic program that makes muscle more oxidative. SLU-PP-332 can switch on parts of that program in mice; it does not reproduce mechanical loading, skill practice, cardiovascular shear stress, bone loading, or every adaptation of exercise.

How It Works

ERR nuclear receptors coordinate genes involved in mitochondrial biogenesis, fatty-acid oxidation, oxidative muscle fibers, and cardiac metabolism. In mice, injected SLU-PP-332 increased endurance and energy expenditure and improved metabolic or cardiac outcomes in several disease models.

This is transcriptional pharmacology, so an effect—if humans had one—would be expected to develop through altered gene expression over days rather than as a stimulant rush.

Dose and How It Is Taken

There is no validated human dose or route. Published efficacy studies used intraperitoneal dosing in mice, commonly 25–50 mg/kg. Animal-to-human arithmetic cannot establish a safe exposure, especially when absorption and metabolism are unknown.

SLU-PP-332 is highly lipophilic and has very low aqueous solubility. It also shows poor human-liver-microsome stability, with an in-vitro half-life around 31 minutes in recent optimization work. These properties are why newer analogs are being developed; they do not validate DMSO-like injectable solvents or oral vendor capsules.

• Human oral or injected bioavailability: Unknown.
• Subjective onset, pharmacologic onset, Tmax, plasma half-life, duration, accumulation, full effect, and complete elimination: Unknown.
• Food effect: Unknown.
• BBB penetration and CNS selectivity: Not established in humans.

Chemical-optimization study

Timing and Pharmacokinetics

• Absorption/bioavailability: Unknown in humans for every proposed route.
• Full practical effect: Unknown; mouse gene-expression and endurance outcomes followed experimental exposure, not a validated human clock.
• Subjective duration: Unknown because there is no controlled human phenomenology.
• Half-life: Unknown in humans.
• Accumulation/steady state: Unknown in humans.
• Near-complete elimination: Cannot be calculated without human PK.
• Metabolism/elimination: Human metabolic enzymes, metabolites, and excretion fractions are unknown.

Evidence and Experiences

All efficacy evidence is cellular or animal. No registered, peer-reviewed human administration study establishes safety, PK, exercise performance, fat loss, or cognition. Anti-doping laboratories are already developing detection methods, which shows interest—not human safety.

Forum users themselves repeatedly note that human protocols do not exist; reports also call it a “dud.” This is precisely the setting in which mislabeled material, expectancy, and survivorship bias can manufacture a fake dose culture. Oral-bioavailability discussion, mixed anecdotal discussion

Safety, Interactions, and Monitoring

Human organ toxicity, cardiac rhythm effects, reproductive biology, cancer risk, endocrine interactions, immunological effects, and long-term ERR adaptation are unknown. ERRs are widespread metabolic regulators; “estrogen-related” does not mean hormonally inert.

Avoid human use, particularly in minors, pregnancy, breastfeeding, athletes subject to anti-doping rules, active cancer, heart disease, and combination metabolic-drug regimens. There is no evidence-based cycle or washout.

A legitimate first-in-human program would require GLP toxicology, formulation work, ECG and imaging, full metabolic and reproductive monitoring, dose escalation, PK, and long follow-up. A vendor purity chromatogram is nowhere near that standard.

Human tolerance, dependence, withdrawal, and a safe cycle are unknown. A fading sensation would not prove that ERR-driven transcriptional effects had ended.

Bottom Line

SLU-PP-332 is a valuable mouse research probe that activates part of the endurance-exercise gene program. It currently has no human dose, PK, or safety basis, and its poor solubility and metabolic stability make commercial self-experimentation even less interpretable.

18.11 Actoprotectors and Antihypoxic Metabolic Modulators​

An actoprotector is intended to preserve work under harsh physical or metabolic stress without ordinary psychostimulation. Bemitil, Hypoxen, and meldonium have regional histories, but evidence quality, product comparability, and anti-doping consequences require unusually careful labeling.

18.11.1 Bemitil / Bemethyl — Stress-Resistance That Builds Across Several Days

What it is: Bemitil—also spelled bemethyl, bemithyl, or metaprot—is 2-ethylbenzimidazole hydrobromide, a Soviet-developed actoprotector. An actoprotector is intended to increase work capacity under heat, hypoxia, illness, or exhaustive demand without acting like a classic psychostimulant.

What it may feel like: It may be subtle at rest and much clearer under strain. Reports describe being awake and ready to move, breathing and exertion feeling less punishing, and recovering faster after hard work. Others experience restlessness, irritability, headache, nausea, facial warmth, or insomnia. The important image is not forced motivation; it is discovering during the fifth difficult hour that the body and brain are degrading less rapidly than expected.

The simplest description: Bemitil appears to increase production of enzymes and protective proteins that help cells process fuel and withstand stress. It is closer to preparing a factory for a heat wave than borrowing energy from tomorrow with amphetamine.

How It Works

Older Russian literature describes increased transcription and synthesis of enzymes involved in gluconeogenesis, mitochondrial energy production, and antioxidant defense. Bemitil may help recycle lactate and maintain carbohydrate supply during repeated work, while reducing oxidative and heat stress.

This mechanism develops over time. A first capsule may produce little, while repeated exposure across three to five days was reported to build the effect. Mechanistic claims rely heavily on older regional studies and should not be treated as modern target-validation.

Dose and How It Is Taken

Historical medical and performance literature commonly describes 250 mg twice daily after food, often for two-to-five-day courses with breaks. Other weight-based regimens exist. These are historical exposures, not a modern recommendation for a healthy teenager.

Bemitil hydrobromide is orally absorbed and carbohydrate-rich food reportedly accelerates absorption; taking it after a meal also reduces stomach irritation. It crosses the blood–brain barrier. Exact aqueous/lipid solubility, pH behavior, and formulation bioequivalence are not adequately documented in accessible modern sources.

Timing and Pharmacokinetics

• Subjective onset: Roughly one to three hours when an acute effect is noticed.
• Tmax: A dependable modern human value is not publicly established.
• Absorption/bioavailability: Described as fully absorbed in older reviews, but a modern absolute percentage is unavailable.
• Full practical effect: Builds during the first three to five days of a course.
• Half-life and complete elimination: Modern numeric human values are inadequately published; a dosing schedule cannot substitute for measured PK.
• Accumulation/steady state: Functional effect increases over several days, but parent-drug accumulation has not been cleanly separated from induced protein expression.
• Metabolism/elimination: Hepatic biotransformation followed by urinary excretion of drug-related material.

Actoprotector pharmacology review

• Subjective duration: When noticed, reports describe several hours of greater stress resistance; the course-level effect can build across days.
• Near-complete elimination: Cannot be calculated from dependable modern human parent-drug PK.

Evidence and Experiences

The literature includes military, occupational, illness-recovery, heat, altitude, and exercise studies, but much is old, regional, poorly accessible, and below current reporting standards. There is no large modern program demonstrating grades, intelligence, or safe chronic enhancement in healthy adults.

A detailed forum guide reports major changes in resilience, while a stacked experiment with meldonium and Hypoxen described non-jittery wakefulness, easier running, and lingering restlessness. Because the stack contained three agents, it cannot show what bemitil did alone. Single-compound guide, stacked experience

Safety, Interactions, and Monitoring

Possible effects include nausea, abdominal discomfort, headache, facial flushing, activation, irritability, restlessness, and insomnia. Older sources describe liver metabolism, making hepatic disease and multi-drug combinations relevant. Long-term reproductive, cardiovascular, psychiatric, and cancer safety is insufficiently characterized.

Avoid unsupervised use in minors, pregnancy, breastfeeding, serious liver or kidney disease, unstable psychiatric states, and elite sport without checking current anti-doping status. Stop for jaundice, severe agitation, allergic reaction, chest pain, fainting, or persistent insomnia.

There is no modern evidence-based cycling rule, though historical short courses and rest days reflect the tendency for effect and adverse activation to build. Track sleep, blood pressure, heart rate, exercise or work output, recovery, liver markers when appropriate, and product identity. Old brand names do not verify a current tablet.

Tolerance, dependence, withdrawal, and an evidence-based enhancement cycle are not adequately characterized; a multi-day course in regional practice is not proof that cycling prevents risk.

Bottom Line

Bemitil is a historically important actoprotector whose most plausible value appears during genuine stress, not ordinary rest. It may let capacity decay more slowly and recovery occur faster, but modern PK, replication, product quality, and long-term safety remain far thinner than its reputation.

18.11.2 Hypoxen — A Poorly Defined Antihypoxic Polymer

What it is: Hypoxen, also called olifen, is sodium polydihydroxyphenylene thiosulfonate—a polyphenolic sulfur-containing polymeric drug sold in parts of Eastern Europe and Central Asia. Because it is a polymeric mixture rather than one small, perfectly uniform molecule, batch and analytical identity are unusually important.

What it may feel like: A clean solo profile does not exist. Stacked anecdotes describe lighter breathing, sustained alertness, and less exhaustion during running; other users report nothing clear. If it works, the relevant feeling would appear under low-oxygen or high-demand conditions as slower fatigue—not as euphoria.

The simplest description: Hypoxen is claimed to help electrons and antioxidant chemistry keep moving when oxygen is scarce. The evidence is too weak to say exactly where or how reliably that happens in humans.

How It Works

Regional descriptions propose that Hypoxen supports mitochondrial respiration, accepts reducing equivalents, reduces oxygen consumption for a given workload, and limits lipid oxidation. Modern independent target and structure–activity work is sparse, so the popular phrase “direct electron shuttle” is more confident than the evidence allows.

The polymeric chemistry also means “mechanism” may represent a mixture of redox-active units rather than one receptor interaction.


@Volpa #Volpamogs

finally

 

[mangotimer]

i will read

 

[enchanted_elixir]

i will read

Still polishing the thread though but feel free to go ahead.